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ABSTRACT
William L. Ince: Evolution of the Human Immunodeficiency Virus Type 1 Envelope
Glycoprotein During Chronic Infection
(under the direction of Ronald Swanstrom)
A hallmark of Human Immunodeficiency Virus Type 1 (HIV-1) chronic
infection is the rapid and continual evolution and diversification of the viral Envelope
glycoprotein (Env), which results in multiple co-existing env genetic variants. Env
mediates virus entry into host cells by engaging the primary receptor CD4 and either
of two coreceptors, CCR5 or CXCR4. CXCR4-tropic variants typically emerge in late
stage disease, coincident very low CD4+ T cell counts and severe
immunosuppression, and rarely establish infection. Over the course of infection, Env
diversifies as a result of immune escape selection and selection for differential
usage of CD4 and co-receptors, presumably in order to expand into new target cell
types, although the selective forces driving Env evolution in late stage disease
remain poorly understood. In the work present here, I examined how variation
affects compartmentalization of genetic and phenotypic subpopulations and the
likely forces driving some of this variation in late stages of infection. First, I used a
heteroduplex tracking assay (HTA) to measure the lifespan of cells producing
different genetic variants in the population by measuring the decay rates of variants
when subjects were placed on suppressive therapy. I found that all variants,
regardless of their co-receptor tropism phenotype, decayed at the same rate
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indicating they are replicating in the same cell types or cell types with similar infected
life spans. I further examined the relationship between CCR5 and emergent CXCR4
variants and found that they frequently recombine, further indicated an overlap in
target cell type. I also examined the evolution of Env in a humanized mouse model. I
found that, consistent with a lack of a strong humoral immune response, Env
evolved a more open conformation and enhanced CD4 affinity. I also found that in
this phenotypic background, CXCR4 –tropic variants emerged, and showed
evidence of tissue compartmentalization. Finally I attempted to link the phenotypes
conferred by a more open Env conformation, that evolved in the immunosuppressed
environment in the mouse, to evolution of CXCR4 and provided evidence that the
environmental constrains of imposed by humoral immunity select against the open
Env conformation that potentiates evolution of CXCR4 tropism.
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CHAPTER 1
INTRODUCTION
Human Immunodeficiency Virus type 1 (HIV-1) is a lentivirus, in the virus
family Retroviridae. Lentiviruses are distinguished from their other family members
by their ability to infect non-dividing cells. These viruses establish chronic infection
with ongoing viral replication in primates (SIV, HIV-1, HIV-2) and non-primate
mammals (FIV, BIV, EAIV, CAEV, VMV). A Key feature of HIV-1, and likely all
retroviruses, is its ability to rapidly evolve (151, 167, 175). The high mutation (174),
recombination (4, 41, 240) and replication rates (113, 304), allow HIV-1 to rapidly
generate large amounts of diversity in order to adapt to a highly dynamic host
environment and persist as a chronic infection. This is particularly evident in the HIV-
1 env gene that encodes the viral envelope glycoprotein (Env), which is responsible
for mediating viral entry into a range of target cell types and is the only surface-
exposed antigen of HIV-1. The high level of variation observed during chronic
infection in this gene is therefore mainly a result of antigenic escape mutations (87,
245), and adaptations to different CD4 receptor and co-receptor densities and co-
receptor types on distinct target cell subsets (97). Whereas viral infection is
established by one or a few variants that give rise to an initially homogeneous
population, the continuously shifting selective forces operating on Env, from a co-
2evolving and then diminishing immune response, to changes in access to different
cell populations, result in continual Env diversification and functional evolution over
the course of chronic infection (87, 267).
This introduction will describe the history of HIV-1 infection in the human
population, natural course of infection in the individual and the viral and host
processes that drive the evolution of HIV-1 Env throughout infection and in late
stages of infection in particular.
1.1 HIV-1 Natural History
1.1.1 Origin of HIV-1
The major HIV-1 lineage, group M, responsible for the global pandemic,
emerged as a zoonotic transmission from Chimpanzee Pan troglodytes troglodytes
to humans in south-central Cameroon (135) in the early part of the 20th century (89).
HIV-1 has since spread throughout the world leaving no continent un-affected
(although unconfirmed in Antarctica) and infecting an estimated 0.8% of the world
population (2009 AIDS Epidemic Update, UNAIDS and WHO 2009). Group M
viruses have diversified into at least 9 genetically distinct subtypes (A, B, C, D, F, G,
H, K) and recombinants thereof, with subtype B predominating in Europe and the
Americas and C predominating in Africa and accounting for the largest share of the
pandemic.  The major modes of HIV-1 transmission include sexual contact (251),
vertical transmission (55), and sharing of contaminated intravenous drug
paraphernalia (66).
31.1.2 Viral Proteins and the Life-Cycle of HIV-1
The HIV-1 genome encodes 4 enzyme activities (reverse transcriptase (RT)
with an associated RNase H activity, integrase (IN) and protease (PR)), 5 structural
proteins encoded in the Gag polyprotein (matrix (MA), capsid (CA), nucleocapsid
(NC), p6), and the Envelope glycoprotein (Env), and 6 accessory proteins (viral
infectivity factor (Vif), Viral protein R (Vpr), Viral protein U (Vpu), Regulator of virion
expression (Rev), Transactivator (Tat), and Negative factor (Nef)). The viral
enzymes and structural proteins are required for replication and are shared among
retroviruses. The ability to productively infect non-dividing cells, a defining feature of
lentiviruses, is mediated by specific accessory protein activities, including nuclear
import and cell-cycle manipulation activities of Vpr(108, 110, 263). Accessory
proteins are also involved in subverting host innate defenses (Vif (269)  and Vpu
(201)) and adaptive immune responses (Nef (45)). Tat and Rev facilitate virus
transcription (242) and nuclear export of un-spliced vRNA (170), respectively.
Several of these accessory proteins, including Vpr, Vpu and Nef, have multiple
activities, some of which are not fully understood.
The virus particle is composed of the core, made up of CA proteins
surrounding the NC-bound dimeric, single-stranded, positive-sense RNA genome.
The core is enveloped by a lipid bi-layer derived from the host cell membrane;
embedded in the envelope is the Env protein, which mediates viral entry into the
target cell. The particle also contains other viral proteins involved in replication
processes through integration and viral gene expression in the newly infected cell,
including the enzymes RT, IN and the accessory protein Vpr (47).
4HIV-1 replicates in CD4+ T cells (54, 140), monocytes (329), and
macrophages (90). Viral entry into the host cell is mediated by Env which binds the
primary receptor CD4 and co-receptor, either of two 7-transmembrane G-protein-
coupled chemokine receptors (GPCR), CXCR4 (18, 61, 79) or CCR5 (14, 71),
inducing virion fusion with the host cell and deposition of the viral core into the
cytoplasm. The need for CCR5 or CXCR4 is shared by several other lentiviruses
such as FIV, BIV, and SIV, in some cases in the capacity as the primary receptor
(75, 78, 307, 308), suggesting the co-receptor and perhaps CXCR4 specifically,
represents a primary primordial receptor for lentiviruses. In addition to CXCR4 and
CCR5, other chemokine-receptor family members have been implicated in HIV-1
entry in cell-culture assays (14, 71, 179), although their significance in vivo  is
unclear.
Once inside the cell, the viral RNA genome is reverse transcribed by RT,
which also possesses DNA-dependant DNA polymerase activity in order to generate
the plus-strand DNA to form a linear double-stranded (ds) DNA copy of the genome.
The resulting viral dsDNA, in a pre-integration complex with RT, IN, and other viral
proteins, is transported to the nucleus where integration into the host genome is
mediated by the enzymatic activity of IN. Viral genes are then expressed from the
integrated provirus by host-cell gene expression mechanisms. Initially, spliced
mRNA coding for Tat, Rev and Nef are produced. This is followed by expression of
partially- and un-spliced mRNA coding for the Gag and Gag-Pro-Pol polyproteins,
Vif, Vpr, Vpu, and Env. Gag and Gag-Pro-Pol are transported to the cell membrane
5where they are cleaved into their constituent proteins by PR and, along with Env,
mediate budding of the nascent virus particle.
1.2 Envelope Structure and Function
HIV-1 Env is a type-1 heterodimeric membrane glycoprotein responsible for
mediating viral entry into the target cell. Env is translated as gp160, which is then
cleaved in a furin-dependant reaction to yield the gp41 transmembrane subunit and
the gp120 surface subunit (102, 266). These subunits form heterodimers that are
assembled on the cell surface to form Env trimers, which are ultimately incorporated
in the membrane of the budding virus particle. The gp120 subunit contains the
binding sites for the receptor and coreceptor, which mediate attachment of the virion
to the cell surface, while the gp41 subunit contains the machinery that mediates
fusion of the apposing viral and cellular membranes.
The gp120 subunit can be divided into several regions based on structure and
function. The inner domain faces inward in the trimer and interacts directly with
gp41. The outer domain is on the outer face of the trimer and contains both the CD4
binding site and components of the coreceptor binding site, which involves both the
inner and outer domains (157). gp120 contains 5 variable loops V1-V5, and 5
interspersed conserved regions (C1-C5). The inner domain contains C1, V1, V2, a
portion of C2, and C5; the outer domain contains a portion of C2, V3, C3, V4, C4
and V5.
The first step of entry involves binding of gp120 to the cellular membrane
glycoprotein CD4, the primary receptor. Conformational changes in gp120 induced
by this initial interaction enhance interactions with CD4 to stabilize the bound state
6(67, 327). Conformational changes induced by CD4 binding also expose the
coreceptor binding site on gp120, which is composed of the bridging sheet, a beta
sheet involving C1 and C2 at the base of the V1 and V2 loops in the inner domain
and C4 in the outer domain, and the V3 loop of the outer domain (120). The bridging
sheet and the V3 base interact with the N-terminus of either of two 7-transmembrane
G-protein-coupled receptors, CXCR4 or CCR5 (70, 119, 319). The specificity for the
co-receptor is principally determined by the sequence of the V3 loop, which is also
exposed upon CD4 binding and interacts in a sequence-specific manner with the
second extracellular loop of the co-receptor (39, 50, 306). Binding of the co-receptor
induces conformational changes in gp41 required for fusion, including exposure of
the N-terminal hydrophobic fusion peptide that is inserted into the host cell
membrane, and the folding of the six-helix bundle, processes which bring the
apposing membranes into close proximity and trigger membrane fusion (187).
Many of the structural features of gp120, along with its requirement for CD4
binding, are thought to play a role in masking from antibody recognition and
neutralization important invariant epitopes required for entry (156). These protective
features include the variable loops on both the inner (V1 and V2) and outer (V4 and
V5) domains, which are relatively unconstrained genetically. In it’s unbound trimeric
state, the highly antigenic structures of Env, such as V3, are likely buried beneath
antigenically and conformationally unconstrained epitopes in the variable loops that
can co-adapt with the host humoral response (156). In addition, highly
conformational epitopes, such as the bridging sheet and the CD4 binding site are not
readily available or are too unordered to be recognized by immune surveillance in
7the un-liganded structure. The primary receptor, CD4, can therefore be thought of as
the key that unlocks the door to the functional receptor binding sites for the GPCRs.
Given the conformational changes that must take place in the process of receptor
binding, a replication capacity cost must be associated with these structural
armaments. Alterations in the variable loops and overall structure of gp120 can
enhance CD4 and co-receptor binding, perhaps in a manner that is heavily
constrained by the strong selective forces imposed by adaptive immunity (9, 192,
235).
Env is heavily glycosylated by the host cell, with nearly half of its mass
attributed to asparagine (N)-linked high mannose, hybrid, and complex glycans (2,
162).  Asparagines in the NX(T/S)X2 context, where X is any amino acid but proline,
are targeted by the host glycosylation machinery. The number of potential N-linked
glycosylation sites (PNLGs) in an Env protein is variable with a range or 18 to 33
sites per gp120 molecule in group M HIV-1 isolates (146), with about 20 relatively
conserved sites (198). Glycosylation is important for proper protein folding and also
plays a role in immune evasion by creating a shield of poorly immunogenic and
shifting branched glycans that sterically hinder antibody access to constrained
epitopes (302). Most of the glycosylation sites on gp120 are located in the outer
surface of the outer domain, consistent with their function as an antibody “glycan
shield” (302). Specific PNLGs can also influence CD4 binding, presumably by
altering access to the binding site (74). While many sites are conserved,
glycosylation patterns can be diverse in the virus population; in particular, much of
the length variability in the variable loops V1 and V4 result from insertions and
8deletions of PNLGs (231). Consistent with their proposed functions in immune
evasion, variable loops and glycosylation patterns are subject to diversifying
selection both at the population level and through the course of infection (302).
1.3 The Course of HIV-1 infection
1.3.1 Transmission and Acute Infection
Transmission of HIV-1 is typically a rare event. In about 80% of
transmissions, infection is established by only one variant (1, 134). Importantly, for
subtype B, 98% of infections are established by CCR5-tropic viruses (134). Simian
Immunodeficiency Virus (SIV) infection in Rhesus macaques closely resembles HIV-
1 infection in humans and has therefore provided a useful model for studying the
early events of infection. SIV (and by extension HIV-1) has been shown to first
establish infection of local target cells at the site of mucosal transmission and then
disseminate to draining lymph nodes where CD4+ T cells are in high enough density
to sustain larger amounts of replication (185). This occurs within several days after
transmission; however, plasma viremia remains undetectable. Within the first two
weeks, virus spreads systemically to other lymphoid tissue including the gut-
associated lymphoid tissues (GALT), which harbors large numbers of CD4+CCR5+
activated and resting memory T cells that support rapid exponential increases in viral
replication resulting in profound CD4+ T cell depletion in this tissue (24, 98, 163,
295, 326). Evidence suggests that HIV-1 has evolved to home to this target-cell-rich
compartment through specific interactions between Env and a CD4+ T cell-
expressed GALT-homing receptor, alpha4beta7 integrin (5). GALT-replicating virus
is the major contributor to peak viremia, which is reached by about 2-3 weeks post
9infection in the peripheral blood with viral loads measuring 106-107 copies per ml of
plasma. At peak viremia, the virus population is relatively homogenous as
diversifying selective pressures have yet to act on the virus (134, 256), but viral
diversification rapidly increases soon after the adaptive immune response emerges,
and continues through the course of chronic infection as the virus population adapts
to new cellular niches in a changing host environment, in addition to the adaptive
immune response.
1.3.2 Sources of Genetic Variation
Selection acts on sequence diversity that is generated by multiple
mechanisms during replication. Much of the mutational load of HIV-1 is generated by
the low fidelity of RT when the viral genome is reverse transcribed. One study found
an in vivo mutation rate for HIV-1 to be 3.4x10-5 per bp per round of replication
(~2x10-5 per bp for point mutations), such that 1 in every 5 genomes would be
expected to have a point mutation (174). In addition to point mutations, RT can
introduce insertions and deletions, particularly in homopolymeric regions where
these events are most common. However, many of these mutational events, in
addition to those that lead to frame shifts and nonsense codons, render the protein
product non-functional.
Another possible source of mutations is the activity of the antiviral factor
APOBEC3G/F (A3G), a host cell-encoded cytidine deaminase. WhenA3G  is not
recognized by the viral  countermeasure, it is incorporated into the virus particle
where it lies in wait to act on the nascent minus-strand vDNA as it is exposed during
reverse transcription in the newly infected cell (107, 172). Multiple cytidine
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deaminations along the genome result in G to A substitutions in the plus strand that
can render the provirus “hypermutated” in multiple genes. A3G represents a potent
antiviral mechanism, and HIV-1 has therefore evolved a mechanism to neutralize
this activity through the viral protein Vif, which binds and sequesters human A3G
preventing its incorporation into the budding particle(205, 269). However, protection
is incomplete and many proviruses are found to be hypermutated in human infection
(134). Alternatively, A3G may introduce sub-lethal levels of G-to-A mutations that
actually contribute diversity. Some evidence suggests that A3G-induced G-to-A
mutations can contribute to drug resistance and that A3G plays and important role in
generating viral diversity (130).
Genomic recombination also plays an important role in generating viral
diversity. The high frequency of recombination of about 5 events per genome
between different genetic variants (4, 41, 240), highlights the importance of this
process in generating diversity. Recombination between different viruses occurs
when two or more viruses infect the same cell. The genome dimer can then be
formed from two different genomes, and during reverse transcription in the target cell
template switching by RT between the two genomes generates a recombinant viral
DNA product. Recombination has the effect of generating combinations of mutations
in a single virus more rapidly than sequential mutation, thus increasing more quickly
the genetic diversity upon which selective pressures can act. This is particularly
important in cases where several mutations are required in combination to increase
fitness, as is the case with drug resistance mutations in pro and pol  (195).
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1.3.3 Diversifying Evolution in Env: Adaptation to an Adaptive Immune
Response
Within 3-4 weeks post infection, coincident with peak viremia, a virus-specific
cytotoxic T lymphocite (CTL) response ensues that partially suppresses viremia to a
“set point”, a reduced but relatively stable viral load (22, 93, 149). The level of this
suppression is variable between individuals and higher set points are linked to more
rapid disease progression (21, 149, 182, 197). Around this time, in the relatively
homogenous virus population of early infection, CTL escape variants are detected,
which represent the first signs of diversifying selection in the virus population. The
mechanism of escape from CTL involves selection for amino acid substitutions
within HLA-restricted epitopes that affect antigen processing and antigen
presentation (320). Epitopes are in all viral proteins including Env, which, as the only
viral surface antigen, is also subjected to diversifying selection by the humoral
immune response.
1.4 The Antibody Response to HIV-1 Env
1.4.1 Timing of the Initial Antibodies
The first antibodies to HIV-1 Env are detected within the first 3-4 weeks post
infection, but their ability to neutralize virus at this stage is weak (80, 245, 284, 302).
Neutralizing IgG antibodies are detected starting around 3 months post infection with
escape mutations in the virus appearing soon after (302). The primary epitopes to
which antibodies are directed are in the variable loops (V1-V5) and the receptor
binding site surfaces, including epitopes that are induced by CD4 binding (214, 227,
314, 316). Importantly, sera does not generally neutralize contemporaneous virus,
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and this, along with the observation that neutralization of early virus by sera
collected later in infection wanes over time indicates that virus and the neutralizing
antibody response are co-evolving (87, 302, 305). In Env, this results in a rapid
expansion in diversity and divergence from the founder population that continues
into the chronic phase then levels off in later stages of disease, where diversity can
reach as high as 10% in the env gene (267).
1.4.2 Antibody-Driven Evolution
Consistent with the specificity of most antibodies, escape-associated variation
is primarily identified in the variable loops, excluding V3 (298), an important
exception that will be explored below. Diversification in the variable loops V1/V2 and
V4/V5 during chronic infection is therefore attributed to adaptation to the polyclonal
antibody response to these epitopes (87, 245, 253). Variation develops in the form of
a variety of amino acid substitutions, and insertions and deletions, all of which can
affect the pattern of N-linked glycosylation. Although the relative contribution that
different types of mutations make to antibody escape remains unclear, all of these
changes can affect neutralization sensitivity (238, 254, 270, 302, 310).
The most well characterized antibody-driven evolution in Env is that involving
glycosylation patterns. Variability in glycosylation patterns is thought to play an
important role in antibody escape by sterically hindering antibody access to
neutralization sensitive epitopes (302). While glycans can themselves serve as
antibody epitopes (34, 260), glycan-reactive antibodies like 2G12 are rarely found in
HIV-infected people (12, 261). Changes in glycosylation patterns are affected by
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both point mutations that produce or eliminate NX(S/T)X motifs or by insertions and
deletions of NX(S/T)X motifs in the length variable regions of the variable loops
(254). The involvement of base pair triplet repeats in this process is suggestive of a
mechanism of glycosylation site addition similar to that observed for triplet repeat
expansions implicated in some human genetic diseases (53). Evolution of
glycosylation does not necessarily result in a net change in the number of
glycosylation sites, instead a shifting pattern of both conserved and variable
glycosylation sites is observed (87, 302), although conservation in number may be
specific to subtype B (64, 86). Maintenance of this large number of glycosylation
sites likely incurs a fitness cost in the absence of antibody pressure, a feature of Env
that will be explored further in chapter 3.
1.4.3 Rare and Common Antibody Epitopes
While most antibodies are directed at epitopes in gp120 that are not
neutralization-sensitive in contemporaneous virus, a small number antibodies have
been identified in rare cases that target unusual epitopes and are considered
broadly neutralizing, that is, are able to neutralize a broad spectrum of diverse
primary isolates. These include 2F5 and 4E10 (213, 331, 332) which target the
membrane-proximal region of gp41, 2G12 which is specific for a discontinuous
epitope composed of glycans on the outer domain (34, 260), b12 which is specific
for a discontinuous epitope that overlaps the CD4 binding site (33, 327), and more
recently, the most broad and potent antibody identified to date, PG9 (and the related
somatic variant PG16), which targets an epitope that includes  the conserved V1/V2
base, conserved regions of the V2 loop and V3  but only binds trimeric gp120 (299).
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While antibodies to most of these epitopes are rarely identified in infected
individuals, CD4 binding site-specific antibodies represent a large proportion of
antibodies identified in infections (51, 261), although these antibodies generally do
not exhibit the relatively broad potency of b12. As discussed above, while the CD4
binding site is conserved, conformation and glycosylation at proximal sites play an
important role in occlusion of the conserved epitopes. b12 possesses an unusually
long heavy chain complementary-determining region 3 (CDR H3) that allows it to
penetrate the deeply recessed CD4 binding site that is not accessible to most
antibodies (327).
Other antibodies have been identified that target the highly antigenic and
relatively conserved linear epitope at the tip of the V3 loop. This class of antibody,
which include the well characterized antibodies 447-52D and 19b (46, 264, 330)
neutralize only a subset of primary isolates (13), because of masking of the
conserved V3 epitope by V1/V2 in Env in primary isolates (152, 315). These
antibodies have broadened and more potent neutralizing activity when a CD4-bound
conformation is induced (313). Moreover, antibodies directed at V3 are frequently
identified in chronic infection (51, 191), indicating their potentially important role in
neutralization or as a selective pressure.
Evolutionary pathways to antibody escape can be divided into two categories:
Amino acid substitutions in the targeted epitope itself that directly limit antibody
binding, or substitutions that alter either envelope protein conformation or glycan
placement and thereby limit access to conserved targeted epitopes. Escape from
both CD4 binding site and V3 antibodies appears to be accomplished by the latter
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path in most cases.  Because of the importance of conformation on neutralization
sensitivity to V3 antibodies in particular, and because the tip of the V3 loop contains
a conserved linear epitope relative to other antibody-targeted epitopes, these
antibodies may play a role in selecting for Env conformations, rather than specific
changes in the target epitope, that could impact changes in receptor and co-receptor
binding, a hypothesis that will be further developed and addressed in Chapters 3
and 4.
1.5 Evolution of Env Function
While much of the diversity in Env observed over the course of chronic
infection is attributed to antibody selective pressure, specific changes in CD4 and
coreceptor usage also contribute to increased diversity in the population, though as
alluded to above, antibody selective pressures may be linked to phenotypic changes
in Env. Phenotypic variation in Env has been described for its affinity for the primary
receptor CD4, which affects the ability of the virus to enter cell types with low levels
of receptor, such as macrophage (178, 220, 283), and for its ability to use the
coreceptor CXCR4 as an alternative to CCR5, which impacts it’s ability to infect
target cells that exclusively express CXCR4. The phenotype of the virus that
predominates in early infection requires relatively high levels of CD4 and is
exclusively CCR5-tropic (134), but over the course of infection, Envs emerge, with
variable frequency, that can use low levels of CD4 (macrophage-tropic) and/or have
gained the ability to use CXCR4 (X4 variants).
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1.5.1 Macrophage Tropism
Changes that allow the virus to use low levels of CD4 typically involve
conformational changes in Env. Increased CD4 binding and the ability to efficiently
infect macrophages have been mapped to changes  in V2 (125, 142, 300) and to the
removal of a specific PNLGS at position 386 (74) (amino acid numbering here
forward corresponds to the reference strain HXB2, Genebank accession number
K03455), but not changes in the CD4 contact residues themselves (157), although
exceptions have been found (73). This suggests that the primary mechanism of
enhanced CD4 binding and thus macrophage tropism is through conformational
changes in Env induced by amino acid changes outside of the binding site. These
conformational changes may also enhance the ability to use lower levels of CCR5
expressed on macrophage perhaps by decreasing the dependence on CD4-
triggered conformational change (95).
The selective pressures driving macrophage tropism are not well understood.
Target cell availability could drive macrophage tropism if virus that replicates in
these cells has a selective advantage, as may be the case for virus
compartmentalized in the CNS where macrophage may support viral replication (73,
74, 283). Macrophage-tropic variants have also been identified in alveolar
macrophage in the lung (90, 123) and Kupffer cells in the liver (36). Importantly,
macrophage-tropic variants have not been found to predominate in the peripheral
blood, particularly in early infection (97, 126, 221).
17
1.5.2 CXCR4 Tropism
Another feature of the vast majority of viruses that establish infection is their
exclusive use of the CCR5 coreceptor (R5 variants), a phenotype that is maintained
through the early course of disease and into the chronic phase. In about one-half of
individuals, Env variants emerge that have gained the ability to use the CXCR4 co-
receptor (X4 variants). This phenotypic switch almost invariably coincides with
immunosuppression and progression to AIDS, suggesting that X4 viruses are more
pathogenic (15, 49, 244, 282); however it is still not clear whether or not the
emergence of CXCR4-tropic viruses is the result or the cause of
immunosuppression, an issue that will be discussed below. CXCR4-tropic variants
emerge as a clonal outgrowth from the R5 viral population and often retain the ability
to use CCR5, i.e. they are dual tropic (126) although variants may be functionally
CXCR4-tropic in vivo (318). The primary genetic determinant of CXCR4 tropism is
the V3 loop in which only a few changes at specific positions are required to confer
CXCR4 tropism (117, 127). Genetically, CXCR4 tropism can be defined by the
presence of basic residues at positions 11 and/or 25 of the 35 amino acid V3 loop,
or an increase in overall positive charge (117, 129, 184). Variability in the V3 loop is
therefore indicative of a phenotypic switch in co-receptor tropism (184, 202, 203).
As with macrophage tropism, the selective pressures driving evolution of X4
virus are not well understood, although several hypotheses exist. CXCR4 is
exclusively expressed on the large subset of naïve CD+ T cells, whereas both CCR5
and CXCR4 are expressed on the memory T cell subset. Emergence of CXCR4-
tropic virus may be driven by selection for virus that can expand its host cell range
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and infect naïve T cells (241). While this may be the case, naïve T cells are
abundant at all stages of infection, which does not explain why X4 variants typically
only emerge late in infection. Another hypothesis, that I begin to address in Chapters
3 and 4, is that evolution of CXCR4 tropism requires conformational changes that
are selected against by specific antibody responses that are diminished in the late
stage immunosuppressed environments when X4 viruses are usually detected.
The case has been made that CXCR4 tropism evolution results in increased
pathogenesis, and that the increased cytopathicity often observed in CXCR4-tropic
viruses leads to the increased rate of immune suppression that is associated with
the CXCR4 tropism emergence (15, 244). Alternatively, CXCR4 emergence may be
a consequence of severe immune suppression (114). However, it is also likely that
both are true and that CXCR4 tropism emergence potentiates its persistence,
perhaps by creating a ratchet effect; once immune selective pressures fall below a
threshold, CXCR4-tropic virus can evolve and establish a critical mass in naïve T
cells in particular, initiating an irreversible decline in immune competence. Chapter 2
explores the relationship between CXCR4- and CCR5-tropic virus populations and
attempts to address the question of whether these populations are replicating
independently of each other.
1.6 Compartmentalization
Central to the evolution of HIV during infection is the spread of virus
systemically into different organ and cellular compartments (257, 311). Viral
populations can replicate independently in different tissue locations or cell types and
genetically diverge as a result. Establishment of divergent populations that are
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replicating independently of each other in different niches, or compartments, can
result from a specific adaptation to a particular niche, such as macrophage tropism,
or as a result of stochastic founder effects (85). Given the diversity of HIV-1 genetic
and phenotypic variants coexisting in an individual, it is likely that at least some
subset of these variants are compartmentalized, because the relatively stable
coexistence of these distinct genetic and phenotypic variants implies some degree of
niche selection. Compartmentalization is a common feature in different tissues such
as the CNS, genital tract, and lymphoid tissue (37, 59, 136, 247, 257, 283), and also
in different cell types, as some data suggest (15, 88).
The multiple selective pressures that drive diversification of HIV-1, as
discussed above, result in the multiple genetic and phenotypic variants that are
found to coexist in the peripheral blood. It is possible that different pathways of
neutralizing antibody escape are a result of differential antibody selection in
compartmentalized populations. Different functional Env variants may be emerging
from compartmentalized populations under different selective pressures. In addition,
populations compartmentalized due to stochastic seeding may also be represented
as distinct genetic variants in the periphery, but with no discernable selective
advantage. Chapter 2 attempts to address the degree to which the variants in the
periphery represent compartmentalized populations.
Chapter 2
Major co-existing human immunodeficiency virus type 1 env gene subpopulations in
the peripheral blood are produced by cells with similar turnover rates and show little
evidence of genetic compartmentalization
The following material was published as a manuscript in the Journal of Virology
under the following citation:
William L. Ince, Patrick R. Harrington, Gretja L. Schnell, Milloni Patel-Chhabra,
Christina L. Burch, Prema Menezes, Richard W. Price, Joseph J. Eron Jr. and
Ronald I. Swanstrom. 2009. Major co-existing human immunodeficiency virus
type 1 env gene subpopulations in the peripheral blood are produced by cells
with similar turnover rates and show little evidence of genetic
compartmentalization. J. Virol. 83(9):4068-80.
This material is copyrighted by and reproduced with the permission of the American
Society of Microbiology.
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2.1 ABSTRACT
A distinctive feature of chronic human immunodeficiency virus type 1 (HIV-1)
infection is the presence of multiple co-existing genetic variants, or subpopulations,
that comprise the HIV-1 population detected in the peripheral blood. Analysis of HIV-
1 RNA decay dynamics during the initiation of highly active antiretroviral therapy
(HAART) has been a valuable tool for modeling the life span of infected cells that
produce the bulk HIV-1 population. However, different HIV-1 target cells may have
different turnover rates, and it is not clear whether the bulk HIV-1 RNA decay rate
actually represents a composite of the decay rates of viral subpopulations
compartmentalized in different cellular subsets with different life spans. Using
heteroduplex tracking assays (HTAs) targeting the highly variable V3 or V4-V5
regions of the HIV-1 env gene in eight subjects, we found that all detectable co-
existing HIV-1 variants in the peripheral blood generally decayed at similar rates
during the initiation of HAART, suggesting that all of the variants were produced by
cells with a similar life span. Furthermore, single genome amplification and
coreceptor phenotyping revealed that, in two subjects, co-existing HIV-1 variants
with distinct CXCR4 or CCR5 coreceptor phenotypes decayed with similar rates.
Also, in nine additional subjects, recombination and a lack of genetic
compartmentalization between X4 and R5 variants were observed, suggesting an
overlap in host cell range. Our results suggest that the HIV-1 env subpopulations
detectable in the peripheral blood are produced by cells with a similar life span and
are not genetically isolated within particular cell types.
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2.2 INTRODUCTION
Infection with human immunodeficiency virus type 1 (HIV-1) is typically
established by one or a few variants that give rise to an initially homogeneous viral
population (58, 86, 134, 159). As infection progresses into the chronic phase,
sequence diversification occurs throughout the viral genome, most dramatically in
the envelope gene (env), as a result of selection of humoral and cytotoxic T
lymphocyte (CTL) immune escape mutations (22, 87, 149, 249, 309). Sequence
diversity is clustered in variable regions in the env gene, termed V1 through V5,
which encode surface loops in the Env protein that are important targets of the host
antibody response (87). Diversification of env results in the presence of multiple, co-
existing env variants in the peripheral blood that continually evolve during the course
of infection (106, 139).
Typically, the HIV-1 population early after infection uses CCR5 as the
coreceptor (R5) (134, 292, 324, 328), and variants that can use CXCR4 (X4) arise
later in the disease course in approximately one-half of individuals infected with
subtype B virus (49, 144). A major determinant of coreceptor use is found in the V3
loop, and sequence evolution in this region is often linked to the virus’s ability to use
CXCR4 (81, 129, 202). After the emergence of X4 virus, env genes encoding both
CCR5 and CXCR4 tropism can co-exist for extended periods of time, maintaining a
diverse V3 population (49, 202, 274). Variation in R5 Env proteins can also influence
the ability of a virus to utilize varying levels of CD4 and CCR5 found on different cell
types, such as macrophage and T cells (95, 97, 220, 226, 283, 300).
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Distinct biological characteristics encoded by different env variants, such as
coreceptor use, cellular tropism and sensitivity to immune pressure, may drive, or
result from, HIV-1 compartmentalization. Genetic compartmentalization of HIV-1
variants has been well documented in anatomical compartments, such as the spleen
(42, 85, 96), central nervous system (30, 104, 105, 148, 206, 247) and genital tract
(59, 136, 211, 222, 233), and in different cellular compartments, such as
monocyte/macrophage and CD4+ T cells (88, 168). Divergent coreceptor tropism in
particular may lead to compartmentalization of virus in different cellular subsets. For
example, naïve and memory T lymphocytes both express CXCR4 but differentially
express CCR5 and have been shown to harbor unequal proportions of CXCR4- and
CCR5-tropic viral variants that are concordant with their distinct coreceptor
expression patterns (15, 290).
While genetic compartmentalization of HIV-1 between anatomically or
cellularly segregated sequences has been extensively explored, evidence is limited
as to the extent to which the co-existing env subpopulations circulating in the
peripheral blood represent virus emanating from compartmentalized populations
replicating independently of each other and in different cellular subsets. Although
this question is challenging to address in the context of an infected individual, one
approach stems from the examination of the rate of decay of HIV-1 RNA during the
initiation of highly active antiretroviral therapy (HAART). Effective HAART prevents
new rounds of HIV-1 infection, but cells already infected by HIV-1 continue to
produce virus, and therefore the rate of viral RNA decay during effective HAART
reflects the life span of the HIV-1-producing cells. This strategy was initially used by
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Ho et al. and Wei et al. (113, 303) to characterize the turnover rate of HIV-1-infected
cells. These and subsequent studies (16, 176, 218, 219) suggested that the average
life span of infected cells that produce 99% or more of the bulk HIV-1 population in
the peripheral blood is short, with a half-life of 1-2 days, presumably reflecting the
life span of activated T-cells, whereas cells producing 1% or less of the population
have a half-life measured in weeks, illustrated by a bi-phasic decay curve. However,
the bulk HIV-1 RNA decay rate of the first phase may oversimplify the dynamics of
the underlying viral genetic subpopulations, because this rate may represent an
average without accounting for possible moderate differences between decay rates
of co-existing variants, as might be the case for variants infecting cellular subsets in
different stages of maturation or activation (92, 209, 326). Based on this model, two
or more co-existing viral populations with the same rates of decay during HAART
could be presumed to be produced by the same cellular subset, or at minimum two
or more subsets with the same turnover rate. Conversely, the observation of
different rates of decay would suggest that different cellular subsets are contributing
towards a complex mixture of compartmentalized viral subpopulations.
In this study we characterized the decay rates of co-existing HIV-1 env
variants in the peripheral blood of eight subjects initiating HAART. In two of these
subjects, who possessed both CCR5- and CXCR4-tropic Env variants, we analyzed
the decay rates of each phenotypically divergent env subpopulation. Furthermore, in
an additional nine subjects, we characterized the degree of recombination between
the R5 and X4 subpopulations and the degree to which each subpopulation was
genetically compartmentalized. We found that all detectible HIV-1 env variants in the
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peripheral blood, regardless of coreceptor tropism phenotype, decayed with similar
rates during the initiation of HAART. In addition, we provide evidence of
recombination and a lack of compartmentalization between co-existing X4 and R5
subpopulations, consistent with overlap in their target host-cell populations. Our
findings suggest that the detectable HIV-1 env variants that co-exist in the peripheral
blood are produced by cells with a similar life span and, by this measure, are not
compartmentalized to particular cell types.
2.3 MATERIALS AND METHODS
2.3.1 Study subjects and sampling.
Blood plasma samples used for the variant decay analysis were obtained
from subjects initiating HAART who were recruited either through a previously
described study carried out at the University of California, San Francisco, (subjects
4015, 4021, 4022, 4030, 5005) (276) or at the University of North Carolina, Chapel
Hill, specifically for this study (subjects 101, 106, 108, 109). Sampling of blood
plasma was carried out on the day of treatment initiation and at 1-7 day intervals
post treatment initiation; the median time between samplings for all subjects was 3
days.
Additional blood plasma samples used for the analysis of recombination and
compartmentalization in populations with mixed coreceptor use were excess tissue
obtained from the baseline blood draw of subjects participating in the virology sub-
study of a ritonavir efficacy trial described previously (35) (subjects 1314, 1077,
1551) or from baseline blood draws of subjects entering  ACTG 359 described
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elsewhere (subjects 432, 135, 139, 411, 413, 310) (100). In all cases, written,
informed consent was obtained and all protocols were subject to IRB approval.
2.3.2 Heteroduplex tracking assay and decay analysis.
Viral RNA was extracted from virus particles pelleted from 1 mL of blood
plasma (25,000 x g for 1.5 hours) using the QiaAMP Viral RNA Kit (Qiagen,
Chatsworth, CA). Two, 5 µL aliquots of the 60 µL eluate were amplified in parallel
using the OneStep RT-PCR kit (Qiagen, Chatsworth, CA). The PCR thermocycling
procedures, the primers used to amplify the V3 and V4-V5 regions and the HTA
analysis have been previously described (60, 106, 202). Briefly, PCR products were
annealed to a radiolabeled probe to generate heteroduplexes, which were then
separated in a polyacrylamide gel. Gel-separated heteroduplexes were visualized by
autoradiography and quantitated on a Storm 840 phosphorimager using the
ImageQuant software (Molecular Dynamics/GE, Pittsburgh, PA). The HTA analysis
was modified for this study by using a biotin-radio-labeled probe to facilitate isolation
and sequencing of HTA bands, as described elsewhere (262). All samples were
analyzed in duplicate to verify sampling reproducibility. Samples and time-points that
could not be reproducibly sampled were excluded from the analysis. Viral RNA loads
of individual variants were calculated as a product of the total viral RNA load and the
fractional abundance of each variant. Variant half-lives were calculated using the
time points between which viral load was declining.
2.3.3 Single Genome Amplification.
Viral RNA was extracted as described above. RNA was reverse transcribed
using Superscript III Reverse Transcriptase (RT) System (Invitrogen, CA) and oligo
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dT. A region of the HIV-1 genome encompassing env through 3’ U3 was amplified
using a limiting dilution, semi-nested PCR approach initially described by Simmonds,
et al. (271) and Edmonson and Mullins (76), then modified by Palmer, et al. (212)
and Salazar-Gonzalez, et al. (255). Primers and thermocycling procedures for
amplification and sequencing were used as previously described in Keele, et al.
(134) but modified by replacing the downstream env amplification primer set with a
primer that captures the U3, the sequence of which is 5’-
AAGCACTCAAGGCAAGCTTTATTG-3’. Sequences will be submitted to GeneBank
by the time of publication.
2.3.4 Coreceptor tropism analysis.
Coreceptor phenotype was predicted based on V3 sequences of extracted
HTA bands and SGA amplicons using a Position Specific Scoring Matrix (PSSM)
generated using a training set of V3 sequences from envelopes with known
coreceptor phenotypes on indicator cells expressing CD4 and either CXCR4 or
CCR5 (129). PSSM was implemented through the web portal
http://ubik.microbiol.washington.edu/computing/pssm/.
Phenotypic analysis was carried out as previously described by Kirchherr, et al.
(137), but with modification. Briefly, a CMV promoter containing a 3’ tag matching
the 5’ SGA primer binding site was linked to env SGA amplicons using overlapping
PCR. For the CMV-env linking PCR, the 5’ primer sequence is specific for the start
of the CMV promoter (5’-AGTAATCAATTACGGGGTCATTAGTTCAT-3’), and the
downstream primer (5’-
TGGGTGGCTCTGAAAAGAGCCTTTGGGCTGCTGGCTCAGCTCGTCTCATTCTTT
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C-3’) is specific for a sequence just 3’ of the end of env and contains a histone (H1e)
mRNA 3’ stem-loop tag (underlined) for increased transcript stability. CMV-env
amplicons were co-transfected with the pNL4-3.Luc.R-E- plasmid, obtained from the
NIH ARRRP (108), to generate a pseudotyped, single-cycle luciferase reporter virus.
The coreceptor phenotype of pseudotyped virus was assessed on U87.CD4
indicator cell lines, expressing either CXCR4 or CCR5, obtained from the NIH
ARRRP (14).
2.3.5 Compartmentalization and recombination analysis.
All sequence alignments were generated using MAFFT (Multiple Alignment
using Fast Fourier Transform) (133). Maximum likelihood phylogenies were
generated in PhyML using the HKY85 substitution rate model with the following
parameters: use of four substitution rate categories and estimations of the
transition/transversion rate ratio, proportion of invariant sites and the gamma
distribution parameter (99). A version of the Slatkin-Maddison test for gene flow was
implemented using HyPhy (230, 272) and measures of KST* were obtained using
DNAsp (252). KST* is calculated as described by Hudson, Boos and Kaplan (122).
Briefly, KST* = 1-(KS
*/KT) where KS* is the weighted average of the log of the pairwise
differences within each of the two potentially compartmentalized subpopulations. KT
is the average number of pairwise differences between sequences irrespective of
their grouping.  For both SM and KST* tests, comparison of the observed result to the
distribution of 1000 random permutations of the data was used to obtain a P-value.
Recombination between X4 and R5 variants was detected in sequence alignments
using the bootscan/RECSCAN analysis implemented in the Recombination
29
Detection Program 3 (RDP3) (177, 258). Bootscanning was carried out using a 200
bp window with a 20 bp step and trees were constructed using the Jukes-Cantor
model with 1000 bootstrap replicates.
30
2.4 RESULTS
2.4.1 Decay rates do not vary between detectable env variants that co-exist in
the peripheral blood.
We examined the decay rates of V4-V5 or V3 env variants in chronically
infected subjects initiating HAART to characterize the life span of infected cells that
produce co-existing genetic variants in the peripheral blood. Blood plasma samples
from 8 subjects were drawn every 1-7 days after the initiation of therapy, with a
median interval of 3 days, for up to 3 weeks or over a 1–2 log(10) drop in total viral
RNA load (VL). All subjects in this study achieved suppression of VL to below
detectable levels. RNA was extracted from the plasma samples and then amplified
by RT-PCR to generate amplicons of the variable regions V4-V5 or V3, which were
then subjected to heteroduplex tracking assay (HTA) analysis to resolve the co-
existing sequence variants. The relative abundance of V4-V5 or V3 variants,
potentially comprising as little as 1-3% of the total population, was measured by
phosphorimaging analysis of HTA bands (239, 262). Duplicate RT-PCR reactions
were analyzed to ensure sampling reproducibility; the ability to analyze duplicate
samples to validate the quality of sampling is a key feature of the HTA strategy as
the HTA pattern of two identical, complex populations will appear different if they are
not adequately sampled (111); however, the HTA pattern only represents variants
whose sequence differences cause a shift in migration rate. While much of the
diversity in these highly variable regions of the genome is captured using this
technique, in this work, we are testing the hypothesis that these HTA variants are
markers of potentially compartmentalized populations.
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The decay curves of V4-V5 and V3 HTA variants from two representative
subjects are depicted Figure 2.1. The Log(10) magnitude of the VL drop, the T1/2
(days) of the bulk VL, and the maximum differences in T1/2 for the env variants
detected in each subject are shown in Table 2.1. In all but one subject, virus decay
appeared mono-phasic over the first 1- 2 Log(10) decline in VL. In subject 106, the
VL decay appeared more rapid between the first and second time points (days 0 and
1), which had an apparent T1/2 of 0.28 days (based on a single time-point),
compared to the VL decline between the second and fifth time-points, which had an
apparent T1/2 of 2.22 days (Figure 2.1a). The median bulk VL decay rates for these
subjects was T1/2 =1.7 days. The decay rates of either V3 or V4-V5 variants within
each subject did not vary significantly; the median value for the greatest differences
between any two variants within a subject was 1.6-fold and did not exceed 2-fold
within any subject, likely within the margin of error of this assay. The minor variation
in decay rates of variants did not correlate with their relative abundance, including
for variants comprising as little as 2% of the detected population  (Table 2.1). We
conclude that for variants comprising as little as 2% of the detected population and
representing the first phase of decay: i) variants are not compartmentalized in
anatomical locations or cellular compartments that are differentially targeted by anti-
viral activity; ii) the life spans of potentially different, virus-producing cellular subsets
do not differ to a significant degree for those cells producing the major variants of
env; and iii) variants are not otherwise compartmentalized in a manner that
differentially affects their rates of decay.
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2.4.2 Decay rates do not differ between X4 and R5 variants in the first phase of
decay.
The ability of a virus to use CXCR4 efficiently may allow infection of a
different subset of target cells and hence may result in compartmentalization of X4
and R5 variants in cell types that differentially express these coreceptors, such as
memory and naïve T cell subsets (19). Many X4 variants retain the ability to enter
cells using CCR5 (i.e. dual-tropic), although it is not clear this ability is utilized in vivo
(171, 318). Furthermore, naïve and memory T cell subsets have been shown to be
preferentially infected by CXCR4 or CCR5 variants, respectively (15, 290).
We identified two subjects from the analysis described above who had co-
existing CXCR4- and CCR5-tropic populations, which allowed us to determine the
relative rates of decay of X4 and R5 variants specifically. Coreceptor usage was
assessed by first using PSSM, followed by phenotypic analysis of the encoded Env
protein in a pseudotyped virus entry assay. One subject (109) had a viral population
with both X4 and R5 variants identified by PSSM and confirmed in an entry assay. In
the other subject (101), distinct V3 variants failed to meet the cut-off value for a
CXCR4 tropism designation by PSSM, but exhibited strong CXCR4-tropic activity in
the entry assay. In both of these subjects, X4 variants retained some ability to use
CCR5.
HTA analysis of the V3 and V4-V5 regions of env of virus from subject 109
revealed 2 and 4 HTA variants, respectively (Figure 2.2a and b). Recovery and
sequencing of HTA bands, along with single genome amplification (SGA) and
phylogenetic and phenotypic analysis of full length env genes from the first time-
33
point allowed us to link env sequences, and their coreceptor usage phenotypes, to
the specific V3 and V4-V5 HTA bands for this subject. For example, X4 and R5 V3
variants formed distinct phylogenetic lineages that were each represented by one of
the two HTA variants (Figure 2.3a) and V4-V5 HTA variants were linked to X4 V3
sequences by the presence of a deletion in each variable loop (data not shown). The
full-length env sequences also formed distinct phylogenetic lineages according to V3
genotype and coreceptor phenotype (Figure 2.3b). The decay of X4- and R5-linked
V3 and V4-V5 HTA variants are depicted in Figure 2.2a and b, respectively. The
decay rate of the total VL for subject 109 was T1/2 = 2.3 days, and over the course of
a 2-Log(10) drop in VL, there was no significant difference in the decay rates of HTA
variants relative to each other in subject 109 (Figure 2.2a and b, Table 2.1).
HTA analysis of virus from subject 101 revealed 2 variants in the V4-V5
region that decayed with similar rates (Figure 2.2c, Table 2.1). However, we were
not able to amplify the V3 region from this subject, presumably as a result of
subsequently identified V3 primer binding site mismatches in this viral population. In
an alternative approach taken for this subject, SGA was carried out on each time
point in order to assess the change in the relative proportions of all SGA-amplified
env variants as VL declined. env sequences that exhibited strong X4 usage in the
entry assay clustered together in a phylogenetic tree, as did their V3 sequences,
indicating linkage coreceptor use (Figure 2.4a and b). While not meeting the
threshold value for X4 usage according to PSSM, these V3 variants had distinctly
higher PSSM values and were more positively charged relative to the rest of the
population. V4-V5 genotypes were only weakly linked to tropism (data not shown).
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Weak X4 entry activity was detected in some envelopes whose sequences were
intermingled with those of exclusively R5 envelopes (Figure 2.4a and b), although
the biological significance of this low-level X4 activity is unclear.
The decay rate of the total VL for subject 101 was T1/2 = 2.3 days, and over
the course of a 2-Log(10) drop in VL, there was no significant difference in the decay
rates of V4-V5 HTA variants relative to each other (Figure 2.2c and Table 2.1). In
addition, we did not detect a significant change in the proportion of env sequence
variants, sampled by SGA, that clustered with phenotypically identified X4 or R5
variants at the 2 time points following initiation of therapy. X4 variants  constituted
26% of the amplicons in the first time point and 20% in the third time point, P=0.7
(Figure 2.4a). That we did not detect differential decay of X4 versus R5 variants in
subjects 101 or 109 leads us to conclude that either i) the bulk of the tropism
variants are not compartmentalized between different cellular subsets, or ii) while
tropism variants may be compartmentalized in different cellular subsets, these
infected cells have similar life spans when productively infected. Furthermore, any
differential effects that X4 or R5 infection may have on the life span of the infected
cell, or any difference in susceptibility of these tropic variants to anti-viral inhibition,
are not apparent in these data.
2.4.3 CXCR4 and CCR5-tropic variants exhibit limited genetic
compartmentalization in the peripheral blood.
 We next examined the potential genetic compartmentalization of co-existing
R5 and X4 variants using an alternative approach. Specifically, we were interested in
determining the degree to which viral genomes with distinct coreceptor tropisms
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exhibit signs of genetic compartmentalization. For this analysis, we included the
entry samples of the two subjects identified above (101 and 109) and an additional
nine subjects, obtained from studies described in the Methods section, with co-
existing X4 and R5 subpopulations identified by PSSM analysis of V3 sequences.
Using SGA, which eliminates confounding recombination during PCR, we generated
amplicons containing env, nef and the U3 region of the viral genome and carried out
PSSM and phenotypic analysis on a representative subset of env variants from each
subject. Phenotypic analysis was consistent with the result of the PSSM analysis for
every amplicon tested in all but subject 101, as described above. CXCR4-tropic
variants from all but two subjects in this study (138 and 411) also exhibited CCR5-
tropic activity in the reporter assay, but will be referred to as X4 variants. In many
subjects, phylogenetic analysis of env sequences showed a deep branch point
between the R5 sequences and a monophyletic group (i.e., a group that has
descended from a single ancestral virus) of X4 sequences, suggesting that the
outgrowth of X4 variants derives from a clonal event. Representative examples of
phylogenies of sequences encompassing V1 of env through the 3’ U3 from three
subjects are depicted in Figure 2.5.
If these X4 and R5 variants exist in distinct compartments with no migration of
viruses between compartments, then the independent evolution of these virus
subpopulations will produce a number of evolutionary signatures in regions of the
genome outside of V3. We looked for these signatures using two methods applied to
sequences from three regions of the genome: the V4-V5 region of env, the gp41
region of env, and the U3 region of the LTR. First we used the Slatkin-Maddison
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(SM) test (272) to investigate whether independent evolution of X4 and R5 variants
in distinct compartments had produced similar phylogenetic patterns in all genome
regions. Essentially, our use of the SM test examines the expectation that X4 viruses
should form a monophyletic group regardless of the genome region used to build the
tree, if this group is compartmentalized. Second, we used a distance-based metric,
KST* (see Methods) (34, 74, 89), to investigate whether independent evolution of X4
and R5 variants was occurring in distinct compartments and producing genetic
differentiation between the compartments in regions outside of V3. The KST* statistic
is a measure of whether the genetic distance (number of nucleotide differences)
between the X4 and R5 subpopulations is significantly greater than the genetic
distance among viruses within the X4 or R5 subpopulations. Gene flow between
compartments would erode both of these signatures of independent evolution, and
gene flow is expected to have the strongest impact on genomic regions that are
most distant from V3, due to the increased likelihood of recombination.
Observed SM and KST values were compared to the distribution of 1000
random permutations of branches or sequences to determine the level of
significance of separation. Because X4 and R5 subgroups were essentially defined
by their V3 genotype, which in most subjects were monophyletic groups with highly
similar genotypes, recombination events were inferred when the sequences of the
regions analyzed did not cluster according to their linked V3 genotype, indicated by
migration events in the SM analysis. However, a lack of compartmentalization can
result in increased sequence homogeneity in regions distal to V3, and detection of
recombination between X4 and R5 sequences in these regions is only possible in
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cases where there remain strong phylogenetic signals that result in a well-supported
tree.
The analysis revealed statistical support, by both KST and SM measures, for
compartmentalization of two genetic populations defined by coreceptor use for
markers proximal to V3, such as V4-V5 (Figure 2.6a and b). This would be expected
as mutations closer to the population-defining V3 sequence would likely persist in
linkage disequilibrium for a longer period of time after the outgrowth of the X4 V3
mutations, especially if they are functionally linked to V3. However, in most subjects,
SM migration events between the R5 and X4 populations were increased in regions
more distal to V3, such as U3 (Figure 2.6a), indicating that these populations were
replicating at least part of the time in a shared cell type, providing the opportunity for
recombination. Representative examples of detected recombination between X4 and
R5 sequences and the predicted location of breakpoints, in these cases outside of
gp120, are illustrated in Figure 2.7. This result is consistent with previous
observations of recombination between X4 and R5 viruses made using different
methods (183, 257, 291). We also observed decreasing values of genetic
differentiation between X4 and R5 groups, as measured by KST, for regions farther
from V3 (Figure 2.6b). However, in several subjects (135, 411, 432, 1314) a
compartmentalization signal in the U3 remained statistically significant, if decreased,
by both measures (Figure 2.6a and b, bottom panels). Taken together, these results
show that while X4 and R5 env variants are genetically distinct, in many of our
subjects there is little evidence of genetic compartmentalization between X4 and R5
variants in regions outside of env, such as in the U3.
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2.5 DISCUSSION
There are several reasons to hypothesize that variants that appear in the
blood are potentially compartmentalized. Previous studies have demonstrated
compartmentalization of HIV-1 variants between different anatomical compartments,
such as the central nervous system, genital tract, and different lymphoid tissues (59,
68, 96, 101, 136, 148, 233, 247, 257, 268, 289) as well as tissue microenvironments
(96). The gut-associated lymphoid tissue in particular represents a major source of
active replication of potentially compartmentalized CCR5-tropic virus populations (5,
228, 289, 295). It is possible that virus spatially compartmentalized in these
anatomical sites may be represented as distinct variants in the peripheral blood.
Because the initiation of HAART abruptly blocks new rounds of HIV-1 infection,
presumably without impacting viral RNA production from cells already infected,
different decay rates of compartmentalized variants following suppression of viral
replication should reflect different life spans of the cells from which they are
emerging. Viral populations compartmentalized in either cell types or tissues that
experience differential drug exposure may also decay at different rates if viral
replication continues at some level in the presence of suboptimal drug concentration.
However, our observation that all detectable HIV-1 genetic variants declined at
comparable rates suggests that the vast majority of the co-existing HIV-1
subpopulations in the peripheral blood are neither compartmentalized to cell types
with different life spans nor to cells or tissues with varying degrees of antiretroviral
drug bioavailability.
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Our use of the HTA allowed for relatively sensitive detection of variants
potentially comprising as little as 1-3% of the population (111, 262). However, one
important limitation of this study is the sensitivity for detection of minority viral
populations below this 1% threshold, which may be produced by cells with different
life spans. Such viral populations almost certainly exist based on the biphasic decay
kinetics of the bulk HIV-1 RNA load during HAART (16, 176, 218). It has been
hypothesized that the second phase of decay of the bulk HIV-1 RNA load represents
virus produced by cells with a longer life span, presumably cells of the monocyte
lineage. Compartmentalization of viral DNA populations between CD4+ T cells and
monocytes has been reported (88, 168, 329), and assuming monocytes have longer
half-lives relative to activated CD4+ T cells, variants compartmentalized in these
different cell types would be expected to exhibit different rates of decay during
HAART (52, 113, 218, 303). However, the proportion of variants compartmentalized
in productively infected monocytes may be too small to be detected in our assay
(218, 219), and monocytes may not be productively infected and only produce virus
upon differentiation and entry into tissue (243, 273). Furthermore, the decay
characteristics of HIV-1 upon initiation of therapy that includes an integrase inhibitor
suggest that much of the second phase of decay observed in conventional therapy
represents cells that are slowly undergoing integration, and that the proportion of
productively infected, long-lived cells is smaller than previously thought (196, 265).
Another limitation of this study is that it depends on the assumption that
compartmentalized subpopulations can be distinguished by their env genotypes, and
in particular, genotypes that can be resolved by HTA. However, in addition to its
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function in determining host cell tropism, the extreme genetic complexity of env
within infected individuals makes it a highly sensitive target for the detection of co-
existing viral subpopulations, and any other genomic region that may drive HIV-1
compartmentalization would likely be linked to distinct env variants as a result of
founder effects, genetic isolation or compartment-specific evolution. Furthermore,
any compartmentalized variants would have likely diverged enough to be resolved
by HTA analysis (105). Thus, we can conservatively conclude that the lack of
genetic compartmentalization and differential decay rates observed in this study
applies to the bulk of the HIV-1 population in the peripheral blood that represents
primarily the first phase of viral RNA decay during HAART.
Another potential opportunity for cellular compartmentalization is between
naïve and memory CD4+ T cells. While naïve and memory T cells express similar
levels of CXCR4, CCR5 is expressed only memory cells (19, 160, 204). Previous
studies have found a wide range of preferential infection by, and potential
compartmentalization of, X4 and R5 variants in these cell types, in a manner
consistent with their coreceptor expression patterns (15, 207, 290). If X4 and R5
variants are compartmentalized in these two cell types to a significant degree, then
similarity in decay rates would indicate that the life span of infected naïve and
memory cells are similar when they become activated and produce virus. It is
thought that the bulk of viral replication occurs in activated CD4+ memory T-cells
(113, 176, 218, 275, 277, 326), in which case any potential compartmentalization of
R5 and X4 variants observed in resting memory and naïve cells may represent only
a small fraction of the total population.  Also, activated and previously activated T
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cells express both CCR5 and CXCR4 (19, 204, 208), providing a potential source of
mixing of R5 and X4 variants. There is evidence to suggest that the pool of cells
supporting the bulk of virus replication is not homogeneous in its susceptibility to
infection by X4 and R5 variants (92) and that X4 and R5 variants may be
differentially affected by antiretroviral therapy (92, 223). However, we found no
difference in the decay rates of X4 and R5 variants upon initiation of therapy, and
that the decay rates of these variants is within the range reported in other studies for
the first phase of decay, presumably reflecting the life span of the activated memory
cells supporting ~99% of the virus population (113, 176, 218, 219, 303). This finding
is consistent with a model where virus is emerging from a homogeneous pool of
cells that is sufficiently susceptible to infection by both X4 and R5 variants to
account for most of the production of these variants found in the periphery. This is
also further supported by the finding of a lack of genetic compartmentalization
between X4 and R5 populations in both subjects 101 and 109, for regions outside of
env, indicating some overlap of target-cell types. However, the lack of data indicating
differential decay rates of variants does not allow a definitive conclusion to be drawn
regarding the half-lives of infected cells in different cellular subsets until the degree
of cellular compartmentalization of X4 and R5 variants can be more fully and directly
accounted for in studies of this type. 
The divergent X4 and R5 lineages indicate some degree of genetic
compartmentalization between these variants. This could be due to physical isolation
in different cell types or due to genetic linkage selected across env for the ability to
use different coreceptors. However, we detected an overall lack of
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compartmentalization and evidence of recombination between these populations in
sequence regions increasingly distal 3' of V3, suggesting the potential for sequence
mixing between R5 and X4 variants in a co-infected cell (Figure 2.6 and 2.7). This
observation is consistent with previous reports which have identified X4/R5
recombinants both within env and between env and other regions of the genome
(183, 257, 291). However, our use of the single genome amplification approach
avoided the possibility of recombination during PCR, which may have created
artificial recombinants in some previous studies. These data support the conclusion
that while X4 and R5 variants may preferentially replicate in distinct cellular
compartments, they are not genetically isolated and must with some frequency infect
the same cell types. Still, the deep branch-points in the phylogenetic trees suggest
the initial outgrowth of X4 variants is from a monoclonal genotype.
This study found little evidence for differential decay and
compartmentalization of env variants comprising the bulk of the virus in the
peripheral blood, even in the case of divergent coreceptor phenotypes, indicating
that HAART is equally effective on all the detectible variants making up the bulk
virus in the peripheral blood. However, new technologies are becoming available
that will allow sampling to below 1% (186), and the application of these technologies
may yet reveal minor populations that exhibit differential rates of decay upon
initiation of therapy.
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Patient 
ID V3 V4/5
Starting 
VL 
LOG(10)
CD4 
Count
LOG(10) 
viral load 
drop
T1/2 
(days) 
bulk
% least 
variantC
Max  fold 
difference 
T1/2
d 
101a NA 2 4.5 201 1.9 2.30 19 1.09 (V4/5)
106 3 7 4.7 421 2.3 0.90b 5 1.14 (V3)
108 3 5 4.3 158 1.6 0.76 2 1.16 (V4/5)
109a 2 4 4.9 23 2.1 1.09 11 1.24 (V45)
4015 NA 2 5.1 na 1.4 2.14 9 1.73
4021 NA 9 5.0 na 1.0 1.20 2 2.0
4022 NA 4 4.6 na 1.9 2.09 3 1.58
5005 NA 4 5.3 na 1.5 2.27 2 1.60
aSubjects with mixed-tropic viral populations
bCalculated using the first and last time-points
cPercent relative abundance of the least abundant variant detected
dLargest fold difference in half-life between any two variants
HTA variant 
number
TABLE 2.1. Subject characteristics and viral decay rates
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Figure 2.1. HTA and variant decay analysis of V3 and V4-V5 envelope regions for
subjects 106 (a and b) and 108 (c and d). Left panels depict HTA gel lanes for
the first and last time points. Numbered arrows designate reproducible HTA
variants. Asterisks indicate single stranded probe bands. Right panels are plots of
the viral loads for individual variants (Var) at each time point sampled. Error bars:
standard deviation of 2 replicates. In subject 108 (c and d), a decline in viral load
was not seen until after the second sampling time-point; therefore the decay rate
was calculated from the second time-point in this subject.
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Figure 2.2. HTA variant decay analysis of V3 and V4-V5 envelope regions for
subjects 109 (a and b) and 101 (c) (V4-V5 only). Left panels depict HTA gel lanes for
the first and last time points. Numbered arrows designate reproducible HTA variants.
Single and double asterisks indicate single stranded and double stranded probe
bands. Right panels are plots of the viral loads for individual variants (Var) at each
time-point sampled. Error bars: standard deviation of 2 replicates. Dashed lines
indicate V3 and V4-V5 HTA variants linked to X4 usage.
47
Figure 2.3. Maximum likelihood phylogenies of the V3 region (a) and full-length env
(b) for subject 109. Node labels represent bootstrap values using 100 replicates.
Italicized, bolded tip labels indicate env variants predicted to be X4 by PSSM.
Circles indicate an entry assay R5 phenotype; squares indicate an entry assay X4
phenotype. The V3 tree (a) was rooted at the midpoint. The env tree (b) was rooted
using the env sequence of the molecular clone YU2. V3 HTA variant sequences 1
and 2 correspond to variants in Figure 2.2a.
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Figure 2.4. Maximum likelihood phylogenies of env (a) and V3 (b) sequences from
the first and last time-points of subject 101. Node labels represent bootstrap values
from 100 replicates. Trees were rooted using the molecular clone YU2. Closed
circles indicate an entry assay R5 phenotype, squares indicate an entry assay X4
phenotype, and open circles indicate dual-tropic envelopes with weak X4 usage in
an entry assay.
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Figure 2.5. Maximum likelihood phylogenies of sequences encompassing env,
(starting at V1), nef and U3 from three representative subjects with distinct X4/dual
and R5 populations. Node labels represent bootstrap values from 100 replicates.
Italicized, bolded tip labels indicate env variants predicted to be X4 by PSSM and
confirmed in an entry assay.
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Figure 2.6. Analysis of compartmentalization of 4 genome regions between X4 and
R5 variants. (a) Top panel: Slatkin-Maddison test branch migration events between
X4 and R5 sequences; bottom panel: corresponding P-values for support of
compartmentalization for each region as determined in the Slatkin-Maddison test. (b)
Top panel: KST* values; bottom panel: corresponding P-values for support of
compartmentalization between X4 and R5 variants for each genome region as
determined by the KST* test. Dashed line indicates P=0.05.
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Figure 2.7. Representative examples of recombination between X4 and R5 variants
in subjects 1551 (A) and 411 (B) Top panels: bootscanning plots identifying
recombination break points. The horizontal axis indicates the nucleotide position in
the putative recombinant (query sequence) and in the genomic regions mapped
within the plot. The vertical axis is the % bootstrap support (1000 replicates) for
clustering of the query sequence with either the R5 (grey) or X4 (black) putative
parental sequences. Bottom: Maximum likelihood trees of V3 (left) and U3 (right)
regions indicated in the bootscan plots. X4 variants are italicized and bolded.
Recombinants are boxed and putative parents are circled
Chapter 3
Evolution of the HIV-1 env Gene in the Rag2-/-γC
-/- Humanized Mouse Model
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-/- Humanized
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3.1 ABSTRACT
Rag2-/-γC
-/- mice transplanted with human hematopoietic stem cells (DKO-hu-
HSC) mimic aspects of human infection with human immunodeficiency virus type 1
(HIV-1) including sustained viral replication and CD4+ T cell decline. However, the
extent of HIV-1 evolution in a long-term infection in these humanized mice, a key
feature of the natural infection, has not been fully assessed. In this study, we
examined the type of genotypic and phenotypic changes in the viral env gene that
occur in the viral populations of DKO-hu-HSC mice infected with the CCR5-tropic
isolate HIV-1JRCSF for up to 44 weeks. The mean rate of divergence of viral
populations in mice was similar to that observed in a cohort of humans during a
similar period of infection. Many amino acid substitutions were common across mice,
including losses of N-linked glycosylation sites and substitutions in the CD4 binding
site and in CD4-induced epitopes, indicating common selective pressures between
mice. In addition, env variants evolved sensitivity to antibodies directed at V3,
suggesting a more open conformation for Env. This phenotypic change was
associated with increased CD4 binding efficiency and was attributed to specific
amino acid substitutions. In one mouse, env variants emerged that exhibited a
CXCR4-tropic phenotype. These sequences were compartmentalized in the
mesenteric lymph node. In summary, viral populations in these mice exhibited a
dynamic behavior that included sequence evolution, compartmentalization, and the
appearance of distinct phenotypic changes. Thus, humanized mice offer a useful
model for studying evolutionary processes of HIV-1 in a complex host environment.
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3.2 INTRODUCTION
Animal models of HIV-1 infection are important tools for understanding
transmission, replication, and pathogenesis, as well as therapeutic intervention, of
HIV-1 infection. Non-human primates, such as Rhesus macaques infected with
Simian or chimeric Simian/Human Immunodeficiency Viruses (SIV or SHIV),
represent well-characterized and highly relevant models; however, key limitations
include expense, genetic variability of the host animals, and the fact that SIV, while
closely related, is distinct from HIV-1. Therefore, small animal models that support
HIV-1 infection and recapitulate many aspects of the human infection have been
sought using several approaches.
Recent approaches have involved the use of genetically immunodeficient
mice that have been reconstituted using human-derived hematopoietic stem cells
(HSC) (known as humanized mice). Several models have been developed based on
this approach, including the Rag2-/-γC
-/- (DKO) and NOD/SCID/γC
-/- (NOG or NSG)
mice transplanted with human HSC (NOG-hu-HSC or DKO-hu-HSC) (128, 285) as
well as the NOD/SCID mouse with transplanted human fetal thymus and liver tissue
in addition to HSC (181). These models all support HIV-1 infection (3, 7, 11, 94, 279,
301, 323) (for a review of these models see Denton et al. (63)). The DKO-hu-HSC
mouse lacks both recombination activating gene 2 (Rag2) and the cytokine receptor
common gamma chain (γc) and as a result does not generate murine T, B and
natural killer (NK) cells, but supports engraftment of HSCs and differentiation of
human myeloid and lymphoid lineages. Immune reconstitution in this model likely
involves education of human T cells in the mouse thymus, and dissemination of
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differentiated human lymphoid subsets into the peripheral blood and to multiple
lymphoid tissues including lymph nodes, spleen and bone marrow (285). The DKO-
hu-HSC mouse along with the other humanized mouse models has been used in
studies of transmission (10, 62), pathogenesis (131) and viral inhibition (43, 62, 154,
280, 288).
One important feature of HIV-1 infection is the diversification and evolution of
the viral genome over the course of infection. Diversification occurs most
prominently in the envelope (env) gene, which encodes the viral surface glycoprotein
(Env). Env mediates viral entry into cells through attachment to the primary receptor
CD4, which primes Env for engagement with a co-receptor, either CCR5 or CXCR4,
triggering virion fusion with the cellular plasma membrane (155). HIV-1 infection is
typically established by one or a few CCR5-tropic (R5) variants that give rise to an
initially homogenous viral population, which then diversifies over the course of
chronic infection (134, 267). Diversification of Env results from immune selective
pressures (87), isolation in or adaptation to different cellular and anatomical
compartments (59, 88, 104, 136, 148), and selection for altered CD4 affinity (226,
283, 300) and co-receptor tropism (81, 126). In many cases, during late stage
infection, variants emerge from the R5 virus population that are CXCR4-tropic (X4),
an event that is often associated with accelerated CD4 T cell loss and progression to
AIDS (15, 48, 282). In an effort to determine if any of these aspects of HIV-1
evolution are exhibited in the humanized mouse model, we examined the extent of
HIV-1 diversification and the types of evolutionary changes that occur in env in mice
infected with a CCR5-tropic HIV-1 for up to 44 weeks.
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Sampling of viral env variants from the peripheral blood plasma over the
course of the infection revealed increasing diversity and divergence of the viral
population at rates similar to those observed in natural infection. Mutations were
identified that affected Env conformation and sensitivity to neutralizing antibodies,
CXCR4 co-receptor use, and potential N-linked glycosylation sites. Other mutations
potentially affecting the Env phenotype were identified in CD4 binding sites and
CD4-induced epitopes. The patterns of substitutions indicated that certain sites were
under selection, particularly in cases where the same substitution was identified in
multiple mice.
This study demonstrates the potential for studying HIV-1 evolution in the
DKO-hu-HSC model and also gives insight into the types of selective pressures
driving HIV-1 env evolution in this host environment. These findings, while
highlighting some of the limitations of this model, will help inform its appropriate use
for studying different aspects of HIV-1 infection, such as the evolutionary constraints
placed on HIV-1 during natural infection and in the face of pharmacological and
immunological inhibition.
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3.3 MATERIALS AND METHODS
3.3.1 Model generation.
Rag2-/-γC
-/- immunodeficient newborn mice were injected intrahepatically with
human CD34+ hematopoietic stem cells. Two separate CD34+ cell donors were used
to reconstitute mice 5-8, and mice 64 and 67, respectively (A and B in Table 1). After
8-12 weeks, immune system reconstitution was confirmed. HIV-1JRCSF (GenBank
accession number: M38429.1) virus was generated by transfection of 293T cells with
an infectious clone expression plasmid, pYK-JRCSF (150), obtained from the
National Institutes of Health AIDS Research and Reference Reagent Program
(ARRRP). Cell-free supernatant was used to intravenously infect reconstituted mice.
Five mice from cohort A (4-8) and 4 mice from cohort B (63-67) were infected. Mice
were analyzed from each cohort that were successfully engrafted, successfully
infected and which were kept alive with active infection for at least 22 weeks. Viral
load was monitored for 44 weeks in mice 5-8, and 22 weeks for mice 64 and 67.
As part of an additional study investigating the role of CD4+CD25+Foxp3+ T
regulatory cells (Treg cells) in HIV-1 infection, mice numbered 6-8 were treated at 43
weeks post-infection with denileukin diftitox (DAB389IL-2, denileukin diftitox, or
Ontak), which selectively depletes Tregs (131, 161). Tregs account for between 1-
4% of all CD4+ T cells in this model and Ontak treatment usually results in selective
depletion of Tregs by as much as 90% (131). Treatment with Ontak correlated with
increased immune activation as measured by CD38 expression, and Ontak-treated
mice also exhibited a greater percentage of infected cells and greater CD4+ T cell
depletion. Ontak treatment may have increased viral replication perhaps as an effect
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of global enhancement of CD4+ T cell activation. While there were unique
evolutionary events observed in individual mice, there was no clear distinction in the
patterns of viral evolution between treated and untreated animals.
3.3.2 Sample collection.
Mice were monitored for peripheral blood viral load and CD4/CD8 ratios for
up to 44 weeks. Peripheral blood samples were collected (~30 ul) at 3, 10, 22, 40,
and 44 weeks post infection. Mice were sacrificed and tissue was harvested at 22
weeks (64 and 67) and 44 weeks (5-8) post infection.
3.3.3 Nucleic acid extraction.
Viral RNA was extracted from the available volume of blood plasma (~30 ul)
using the QiaAmp Viral RNA kit (Qiagen, Valencia, CA), eluted in 60 ul diH2O. Total
DNA was extracted from tissue using the PicoPure DNA Extraction kit (Molecular
Devices, Sunnyvale, CA). Pelleted cells extracted from collagenase-treated tissue
(about 105–106 cells) were resuspended in 50 ul of PicoPure buffer containing
Proteinase K. The extraction suspension was incubated at 65°C for 8 hours and
used directly in PCR reactions as described below.
3.3.4 Viral RNA and DNA amplification and sequencing.
The 60 ul RNA eluate was reverse transcribed using the Superscript III
Reverse Transcriptase (RT) System (Invitrogen, Carlsbad, CA) and an oligo dT
primer. A region of the HIV-1 genome encompassing env through 3’ U3 was
amplified from cDNA using a limiting dilution PCR approach (single genome
amplification - SGA) initially described by Simmonds et al. (271) and Edmonson and
Mullins (76), then modified by Palmer et al. (212) and Salazar-Gonzalez et al. (255).
59
Primers and thermocycling procedures for amplification and sequencing were used
as previously described in Keele et al. (134), but modified by replacing the
downstream env amplification primer set with a primer that captures the U3, the
sequence of which is 5’-AAGCACTCAAGGCAAGCTTTATTG-3’. The same
procedure used for amplifying cDNA was used to amplify the envelope gene from
viral DNA extracted from tissue samples. Automated sequencing followed by manual
editing of sequences was carried out on SGA amplicons using the Big Dye
Terminator system (Applied Biosystems, Foster City, CA). GenBank accession
numbers for sequences generated in this study are: GQ412353-GQ412705.
3.3.5 HIV-1 sequencing data from human infections.
Sequences were from Shankarappa et al. 1999 (267) and Salazar-Gonzales
et al. 2009 (256).
3.3.6 Sequence analysis.
Subtype B sequences used for assessment of sequence conservation at
specific sites were accessed through the Los Alamos National Laboratories HIV
Sequence Database (http://www.hiv.lanl.gov). Sequence alignments were generated
using MAFFT (Multiple Alignment using Fast Fourier Transform) (133). The best
fitting substitution rate model for each alignment was determined using FindModel, a
variation of Modeltest (232), implemented through
http://www.hiv.lanl.gov/content/sequence/findmodel/findmodel.html. Maximum
likelihood phylogenies were generated in PhyML using the best fitting model (GTR
or HKY85 in this study), 4 rates substitution categories and the PhyML-determined
gamma shape parameter and number of invariant sites. Potential N-linked
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glycosylation (PNLG) sites were identified using N-Glycosite (325) implemented
through http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html.
Divergence was determined as the mean genetic distance of sequences at a given
time point to the founder sequence. In the case of mouse viral populations, the
founder sequence was that of HIV-1JRCSF, and in the case of human viral
populations, the “founder” sequence was taken to be the consensus of sequences
sampled at a time 2-5 months post-seroconversion for the Shankarappa et al. 1999
sequence set, and an estimated 20-24 days post infection for the Salazar-Gonzales
et al. 2009 sequence set. Distances were determined from ML tree branch lengths
using Branchlength implemented through
http://www.hiv.lanl.gov/content/sequence/BRANCHLENGTH/branchlength.html.
Selection analysis was carried out by determining the rates of synonymous
and non-synonymous substitutions (200, 210). Rates were determined using SNAP
(145) as implemented through:
http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP.html. A Wilcoxon
signed rank test was used to compare rates of synonymous and non-
synonymous base substitutions within mouse populations.
Linkage disequilibrium analysis was performed using DNAsp v5 (166).
A Fisher’s exact test was used to determine the significance of non-
synonymous nucleotide substitution associations.
3.3.7 Env phenotype assays.
env gene expression vectors were generated from selected amplicons using
the pcDNA3.1 Directional TOPO Expression kit (Invitrogen, Carlsbad, CA). 293T
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cells were co-transfected with env expression vectors and the pNL4-3.Luc.R-E-
luciferase reporter vector (108) (obtained from ARRRP) using the Fugene
transfection reagent (Roche, Mannheim, Germany) according to the manufacturer’s
protocol to generate pseudovirus. Cells were washed with phosphate buffered saline
8-12 hours after transfection in order to reduce transfection complex carry-over and
background luciferase expression in target cells, which was monitored with an Env-
negative control. Virus supernatant was collected 48 hours after transfection. Co-
receptor phenotype was determined based on detection of luciferase activity in
U87.CD4+ cells expressing either CCR5 or CXCR4 (14) (obtained from ARRRP)
using the Luciferase Assay System kit (Promega, Madison, WI). Pseudovirus was
incubated with U87.CD4.CXCR4/CCR5 cells for 36-48 hours prior to lysis of cells
and measurement of luciferase activity. Co-receptor-dependent viral entry was
confirmed using inhibitory concentrations of AMD3100 (112) (CXCR4 inhibitor) or
TAK-779 (6) (CCR5 inhibitor) (both obtained from ARRRP). Sensitivity to
neutralization by the anti-V3 antibodies 447-52D (46) (ARRRP) and 19b (20) (a gift
from Dr. James E. Robinson) was assessed on TZM-BL cells (obtained from
ARRRP), which are permissive to X4 and R5 viruses and contain an integrated, Tat-
responsive luciferase cassette (226). Sensitivity to the anti-CD4 antibody Leu3a
(CD4 Pure) (BD Biosciences, San Jose, CA) was assessed on U87.CD4.CCR5
cells.
Viral fusion kinetics were measured on U87.CD4.CCR5 cells in a 96-well
format in triplicate. Pseudotyped virus supernatant and cells were cooled to 4°C and
spinoculated for 2 hours at this temperature to synchronize entry. Immediately after
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spinoculation, the medium was removed from cells and replaced with medium pre-
warmed to 37°C. The fusion inhibitor T20 (obtained from ARRRP) was added at the
inhibitory concentration of 200 nM at time 0 to the first well and at 5 minute intervals
to successive wells for up to 70 minutes. Time to one-half maximal entry was used
to compare viruses.
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3.4 RESULTS
3.4.1 Diversification and divergence of HIV-1JRCSF over the course of infection
in a mouse model with sustained viral infection.
Six DKO-hu-HSC mice with stable human leukocyte reconstitution were
infected intravenously with HIV-1JRCSF, a CCR5-tropic isolate of HIV-1 generated
from an infectious molecular clone. Viral infection persisted in all mice over the
period of observation: 44 weeks for mice 5, 6, 7 and 8, and 22 weeks for mice 64
and 67 which received HSCs from a different donor (Table 1).The viral RNA load in
the blood exhibited a slow decay of about 1 log10 over the course of 44 weeks in
mice 5-8 (Figure 1), consistent with other reports using this model and different HIV-
1 isolates (7), although the reason for this drop is not known. A relative decline in
CD4 T cells was also observed (Table 1).
Given that these mice were able to support infection for 22- 44 weeks, we
wanted to know if, and to what extent, the viral population had diversified, as is
observed in human infections over a similar period of time. Viral RNA was extracted
from the peripheral blood plasma and subjected to single genome amplification
(SGA) for the entire env gene, a limiting dilution RT-PCR technique designed to
facilitate direct sampling of viral genomes and to avoid PCR-generated mutations
and recombination. Sequence diversification and divergence of HIV-1JRCSF in the
peripheral blood was assessed for a region of env that encodes variable loops 1
(V1) though 5 (V5) of gp120 and at multiple time points: weeks 10, 40 and 44 post
infection for mice 5 and 6; weeks 3, 40 and 44 for mouse 8; and weeks 4 and 22 for
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mice 64 and 67. The median number of sequences sampled from each time point
was 16.5 and ranged between 11 and 39.
A maximum likelihood phylogeny of sequences from the last time points
(week 22 for mice 64 and 67 and week 44 for mice 5-8) from each mouse is
presented in Figure 2. Sequences were generally clustered by mouse, indicating
distinct evolutionary paths that could distinguish mouse viral populations.
For a region of env encompassing C2-V5, the rate of divergence from the founder
virus in the mice was compared to that observed in two datasets from infected
humans initially sampled either prior to seroconversion and at time points 3-19
months later  (Salazar-Gonzales et al. 2009) (256) or after seroconversion and at
time points 9-24 months later  (Shankarappa et al. 1999) (267). In the former study,
viral populations from three subjects were initially sampled prior to seroconversion at
an estimated 20-24 days post infection and 9-16 days prior to seroconversion. In the
latter study, viral populations from 7 subjects were initially sampled within 2-5
months after seroconversion. In both datasets, the viral populations at the first time
points sampled were relatively homogeneous, and these populations were
compared to those present in the later time points. Divergence was determined as
the mean distance (branch length) of sequences in a population at a given time-point
from the “founder” virus sequence, which was either the consensus of sequences
sampled at the first time point in the human infections, or HIV-1JRCSF (accession
number M38429.1) for the mouse infections. The rate of divergence was calculated
by using the mean divergence from the founder of a population at the last time point
measured divided by the time post infection. The mean rate of divergence in mice
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and in the post-seroconversion human data sets was 0.0175%/week (range=0.034-
0.0043%/week) and 0.018%/week (range=0.007-0.030%/week), respectively, which
were statistically indistinguishable (P=0.96) (Figure 3A). The mean rate of
divergence in the pre-to-post-seroconversion dataset was also similar (0.015%/week
range=0.004-0.026%/week, P=0.706) although slightly lower than that observed in
mice. The mean diversity (Figure 3B) in viral populations in humans, extrapolated to
44 weeks, was greater than, but still not statistically different from, that observed in
mice (P=1 for the comparison to the pre-to-post-seroconversion human dataset and
P=0.5338 for the comparison to the post-seroconversion dataset). The rates of
divergence and diversification of HIV-1 in mice fell within the distribution of the rates
measured in the two different human cohorts sampled starting at different points
around the time of seroconversion. These similarities are in spite of the likely
absence of an HIV-1-specific antibody response in the mouse, which is low to
undetectable in this model throughout infection, a selective pressure that plays a
major role in Env divergence and diversification in human infection, post-
seroconversion (87). In this regard, Western blot analyses of plasma from the mice
used in this study, taken early and late after infection, were uniformly negative for
reactivity to HIV-1 antigens (data not shown).  We conclude that there is no major
difference in the evolutionary rate of HIV-1 within env in this mouse model over the
first 44 weeks from the time of infection compared to  an analogous early stage of
human infection, although the selective pressures in these two settings likely differ
(see below).
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3.4.2 Features of env sequence evolution in mice.
We next wanted to examine the types and patterns of nucleotide substitutions
that contribute to diversity. One distinctive mechanism that may contribute to
sequence diversity during natural infection is the activity of the anti-viral factor
APOBEC3G (A3G) (130), which, in spite of the A3G antagonist activity of the viral
Vif protein, can give rise to disproportionate numbers of G-to-A transitions in the plus
strand sequence in natural infection, indicating hypermutation of the nascent minus
strand DNA by A3G (172, 248, 322). Examining env sequences from mice revealed
a subset (1-4%) of hypermutated sequences exhibiting a disproportionate number of
G-to-A  transitions in A3G target motifs in each mouse, indicating that this
mechanism is at work in this model. This observation also suggests that A3G may
be contributing some proportion of G-A transitions observed at A3G recognition sites
in sequences that were not overtly hypermutated.
A key feature of this model is the isogenicity of the hosts, when reconstituted
with the same donor. We were interested to see if any common amino acid
substitution patterns had emerged in different mice. Common amino acid
substitutions represented in viral populations of multiple mice likely represent
selected changes rather than mutations that have grown out due to genetic drift, as
might be the case for substitutions represented in only one mouse.
Substitutions that grew out (i.e. were seen in more than one sequence either
within or between mice) in each mouse viral population are depicted in Figure 4 and
are categorized by their potential functional effects, along with the number of mice in
which they were detected. Within a 380 amino acid long region encompassing V1
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through V5  and much of the conserved region 5 (C5), substitutions at a total of 45
positions grew out. These mutations were concentrated in the variable loop regions
compared to the constant regions of Env (p=0.0001, Fisher’s exact test). However,
no insertions or deletions were observed. Of the substitutions that grew out in mouse
viral populations, 19 were detected in more than one mouse, and each of the four
substitutions that were detected in three or more mice (D167N, N386K/S, N411D/S,
and E482K) were represented in both donor sets (Figure 4).
Evidence of positive selection can also be obtained by determining the ratio of
non-synonymous and synonymous base substitution rates (dN/dS). Ratios greater
than or less than 1 indicate positive or negative selection, respectively. For the env
region encompassing V1-C5, the dN/dS ratio was greater than 1 for viral populations
in mice 6 (1.48) and 8 (1.32), which also showed the highest levels of divergence
(Figure 3), nearly 1 in mouse 67 (1.03) and less than 1 in mice 5 (0.79), 7 (0.82),
and 64 (0.57), although the differences between rates of synonymous and non-
synonymous mutations were only significant in mice 6 (P=0.0126, dN/dS=1.48) and
64 (P=0.0001, dN/dS=0.57). We interpret these results with caution, because this
analysis is limited in its sensitivity when there are too few substitutions to provide
statistical power or when only a few sites are under positive selection, which is often
the case in Env early in infection.
3.4.3 Substitutions identified at multiple potential N-linked glycosylation sites.
Glycosylation of Env at numerous sites has been shown to play a role in
proper protein folding, receptor and coreceptor engagement (165, 229), and in
escape from neutralizing antibodies (40, 141, 302). We identified one substitution,
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S142N in mouse 6, that added a potential N-linked glycosylation (PNLG) sequon
[NX1(S/T)X2, where X represents any amino acid other than proline (91)] in V1 and
adjacent to a preexisting PNGS in HIV-1JRCSF, which remained intact (Figure 4). In
contrast, substitutions that disrupted PNLG sequons were observed at 7 positions
and included (mean frequencies indicated in parentheses) N160K (8%), N187D
(36%), N230S (43%), N241D (5%), N339K/D (8%), N386K/S (86%), N411D/S (40%)
and T413I (36%) (Figure 4). All substitutions, except N160K and N241D, were
detected by week 10. Substitutions N339K/D, N386K/S, N411D/S and T413I were
identified in more than one mouse suggesting that loss of glycosylation at these sites
was under some level of selection, although the low frequency of the N339K/D
substitution at no more than 12% suggests that selection at this site was weak. The
substitutions N386K/S, which rose to the highest frequency in the 3 mice in which it
was detected (mean 86%), and N339K/D are located in V4 and C3 regions,
respectively, and are part of the neutralizing antibody 2G12 epitope. Loss of these
PNLG sites individually and in combination has been shown to confer resistance to
this antibody (173, 287). The PNLG sequon composed of N411 and T413, located in
V4, has been shown to co-vary with a number of other PNLG sequons and likely
plays a role in the glycosylation of Env as a means of antibody escape (231, 302).
The net loss of PNLG sites was widely distributed across Env, indicating that the
heavy glycosylation of Env observed in natural infection may not be required for viral
persistence in this model and may reflect the lack of a strong humoral immune
response. Conversely, maintenance of these glycosylation sites likely has a fitness
cost for replication.
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3.4.4 HIV-1JRCSF evolves to become sensitive to specific anti-V3 antibodies.
Previous studies using the DKO-hu-HSC model have found the humoral
immune response to HIV-1 to be weak (7) or undetectable (3, 94, 323), and we did
not detect any HIV-specific antibodies in the mice in this study. Primary isolates of
HIV-1 passaged in cell culture, in the absence of neutralizing antibody pressure,
evolve to become sensitive to a spectrum of heterologous neutralizing antibodies (9,
192, 312). The antibody 447-52D is specific for a conserved epitope at the tip of the
Env V3 loop and neutralizes viral isolates that are known to have a history of cell-
culture passage, while primary isolates can encode the epitope but remain largely
resistant (13, 46, 264). Sensitivity of cell-culture passaged virus to this and other V3
antibodies, such as 19b, is attributed to a loss of the Env conformation that masks
the V3 epitope (180, 313). We were therefore interested in assessing the extent to
which HIV-1JRCSF, which encodes these V3 epitopes but is resistant to 447-52D, had
evolved sensitivity to this antibody. env clones that included a broad spectrum of
substitutions were generated from the amplicons from 5 mouse populations at the
last time point (week 44 for mice 5-8 and week 22 for mouse 64). Screening of the
env clones generated from these mice for expression of an Env protein with
sensitivity to 447-52D (as tested in a pseudovirus assay) revealed a subset of clones
in 4 of the 5 mice that encoded Env proteins that were neutralization sensitive
compared to the input virus Env (Figure 5A). Two mutually exclusive mutations near
the base of the V2 loop appeared to be linked to neutralization sensitivity, N165R/K
and D167N, as one or the other was present in all neutralization sensitive Envs and
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absent in those that remained resistant (Figure 5A and B). These mutations were
detected early in infection. D167N was detected at week 10 in mice 5 and 6 and
both N165K/R and D167N were present in mice 5 and 6 at week 44. Mice 8 and 64
exhibited only D167N, which was detected in these mice at 22 and 44 weeks post-
infection, respectively. The frequency of these mutations in a population was on
average 36% and 52% for N165R/K and D167N, respectively. Neither mutation was
detected in mouse 7 or 67. When these mutations were reintroduced into the HIV-
1JRCSF env individually, they rendered the virus relatively neutralization sensitive
(Figure 5C). We also tested these mutants, along with several of the 447-52D-
sensitive clones, for sensitivity to another V3-specific antibody, 19b, and obtained
similar results (data not shown). The frequency with which these substitutions were
detected suggests that viruses replicating in these mice, as with virus passaged in
cell culture, were not under strong selection by HIV-1-specific antibodies, and that
these mutations may otherwise confer a selective advantage for an Env function
possibly involving increased CD4 binding affinity, CD4 independence, or more rapid
fusion (118, 143, 188, 193, 235).
In order to determine if increased neutralization sensitivity was linked to CD4
binding affinity, clones were selected that represented a range of sensitivities to the
anti-V3 antibody, from relatively resistant to highly sensitive. Sensitivity to
competitive inhibition by an anti-CD4 antibody, Leu3a, was used to evaluate CD4
binding efficiency. Table 2 shows the relative sensitivities of viruses pseudotyped
with selected Env proteins to inhibition of entry by Leu3a. Env proteins that were
highly sensitive to the anti-V3 antibody, those derived from mouse 6, showed a small
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but significant decrease in sensitivity to Leu3a, while the JRCSF mutants I165K and
D167N, which exhibited intermediate sensitivities to the anti-V3 antibody, exhibited
only a marginal decrease in Leu3a sensitivity. This indicates that these Env proteins
have enhanced CD4 binding. When viral fusion kinetics were measured in a time-of-
addition experiment using T20, we failed to measure an increase in the rate of entry
for any of these clones (data not shown). Although the mutations at positions 165
and 167 conferred only a slight increase in CD4 binding affinity, indicating that other
mutations are likely involved in conferring a stronger phenotype, they are linked to
anti-V3 antibody sensitivity and likely contribute to a more open Env conformation
that potentiates CD4 binding and an increase in replication capacity. This is
consistent with the observation that Envs with these mutations become fixed in
multiple mouse viral populations.
When linkage analysis was performed, two sets of mutations were found to
be in high linkage disequilibrium with each other in multiple mouse viral populations.
Substitutions at positions 165 and 167 exhibited mutual exclusivity in the two mice in
which both substitutions were present (mice 5 and 6), and each was linked to a
different position in the same PNLG sequon occupying position 411-413. In mouse 6
substitutions at position 165 and 167 were linked to PNLG site-disrupting
substitutions at position 413 and 411, respectively (p<0.0001 for both). In mouse 5,
changes at position 165 and 413 were also strongly linked (p<0.001) although
linkage between 167 and 411 was weak. In two other mice (mice 8 and 64) only
substitutions at positions 167 and 411 were present, and in mouse 8, were largely
coincident in the subset of genomes where they appeared (p<0.01). In mouse 64,
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while a substitution at position 167 appeared in 30% of genomes, changes at
position 411 appeared in all genomes. Weak linkage between positions in V3 and
either position in the 411 sequon were also observed in mice 6 and 8. In summary,
the substitutions at positions 165 and 167, themselves implicated in alterations of
envelope structure, showed linkage to mutations that disrupted the same distant
PNLG site, but the linkage was to different positions within the PNLG sequon. It
seems likely that the specific amino acid that removes the carbohydrate attachment
at position 411 has a context-dependent effect based on the substitution at position
165 or 167.
3.4.5 Evolution of co-receptor usage.
HIV-1 infection is primarily established by variants that utilize CCR5 as their
co-receptor for entry into target cells (R5 viruses), but in about half of subtype B
chronic infections, viral variants emerge that can use CXCR4 as their co-receptor
(termed X4 viruses) (49, 144). The sequence of the V3 loop is a strong genetic
determinant of, and can be used to predict, HIV-1 co-receptor phenotype (81, 129,
202). Because HIV-1JRCSF utilized CCR5 exclusively, we were interested in
determining if this virus had evolved to use CXCR4 in any of these animals. Six of
39 (15%) sequences from mouse 6 exhibited an X4-associated genotype with amino
acid substitutions S11G and E25K in V3 (Figure 6B), sites at which variability is
linked to co-receptor switching (184).  In addition, nearly all V3 sequences from
mouse 6 (92%) also had a S5N substitution, which represented a reversion to the
subtype B consensus (Figure 6B). A serine at this position has been linked to CCR5
usage (184), indicating that this reversion may be linked to evolution of an X4
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phenotype. These and additional selected clones from mice 5-8 were tested for their
ability to enter indicator cell lines expressing CD4 and either CXCR4 or CCR5.
Consistent with their sequence prediction, the clones from mouse 6 that exhibited
the genetic features of X4 usage were able to infect a CD4+/CXCR4+ indicator cell
line and were therefore classified has having an X4 phenotype (Figure 6A and B).
Re-introduction of the X4-associated V3 sequence into the original HIV-1JRCSF env
was sufficient to confer CXCR4 tropism in the entry assay (data not shown). X4
variants emerged in the peripheral blood late in infection; they were not detected at
week 40 (0 of 29 sequences) but were detected at week 43 in 3 of 13 sequences
(23%). Thus, HIV-1 has the potential to evolve to use CXCR4 in this model, following
an evolutionary path similar to what is observed in natural infections.
3.4.6 Compartmentalization of phenotypic variants.
HIV-1 can be found in multiple tissue compartments in the course of a human
infection, which in some cases leads to the establishment of isolated, or
compartmentalized, viral populations (311). We were therefore interested in
investigating whether or not variants were compartmentalized in different tissue
compartments in the mouse. Mouse 6 in particular, which harbored an X4 virus
population, provided the opportunity to examine the tissue distribution of variants
with distinct co-receptor phenotypes. Viral env genes (V1-V5) from this mouse were
successfully amplified and sequenced from DNA extracted from spleen (SP), bone
marrow (BM), and mesenteric lymphoid tissue (MLN) using the same limiting dilution
technique employed for plasma RNA. Attempts to amplify viral DNA from the thymus
were unsuccessful. Phylogenetic analysis of sequences recovered from these three
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tissues together with sequences from peripheral blood plasma revealed the distinct
clustering of X4 viruses within the tree, which was suggestive of clonal outgrowth of
the X4 variant (Figure 7). In addition, X4-like variants comprised 95% of variants
identified in the MLN, indicating compartmentalization of this phenotype in this tissue
(p<0.0001). Phenotypic testing of a sample of variants with X4-like V3 sequences
from the MLN confirmed their X4 phenotype (data not shown). Variants recovered
from the spleen were phylogenetically intermingled with those from the peripheral
blood and exhibited the same distribution. With these limited data we cannot
determine if X4 compartmentalization in the MLN is due to stochastic seeding of or
initial evolution in this tissue site, or if X4 viruses have a selective advantage in the
MLN in this model. However, these data do demonstrate the potential for sub-
populations of virus to disseminate, evolve and replicate independently in different
tissues.
Genetic compartmentalization between the MLN and PB was assessed in
mice 7, 8 and 64. Viral DNA was not successfully amplified from other mice or other
tissues. In mice 7 and 8, sequences were well equilibrated between the PB plasma
RNA and MLN tissue DNA. In mouse 64, a single synonymous mutation was
enriched in the MLN (P=0.0001 Fisher’s exact test), providing a second example of
compartmentalization, although the overall genetic divergence between the two
compartments was small (data not shown) and likely not based on phenotypic
differences, at least within the Env protein.
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3.5 DISCUSSION
Current models being used to study various aspects of HIV-1 infection include
the genetically immunodeficient Rag2-/-γC
-/- mouse reconstituted with a human
immune system by transplantation of human hematopoietic stem cells (DKO-hu-
HSC mouse) (3, 7, 11, 94, 323). However, a detailed analysis of viral diversification
and evolution in long-term infections has not been carried out in this system. In this
study we examined the viral populations of DKO-hu-HSC mice with sustained
infection for up to 44 weeks. We found that HIV-1 diversifies at nearly the same rate
observed in human infections. We observed evolution of CXCR4 co-receptor use, a
characteristic of many natural chronic infections. In addition we detected evolution
towards increased sensitivity to a conformation-dependent V3 neutralizing antibody,
increased CD4 binding affinity and a general loss of N-linked glycosylation sites.
 Acute HIV-1 infection in humans is marked by high levels of viral replication.
Within several weeks after infection, the CTL response appears and leads to
suppression of peak viremia (22, 234). Following this initial immune response,
variants emerge that have escaped CTL detection, marking the beginning of
continuing evolution of HIV-1 in response to this selective pressure (22, 234).
Between 4 and 5 weeks post infection (typically), HIV-1-specific antibodies appear
(seroconversion), with some of the antibodies directed against the Env protein that
can potentially select for neutralization escape variants (80, 87, 284). Selection of
immune escape variants results in increasing viral diversity, which begins after
seroconversion and continues into the chronic stage of infection, although the tempo
of immune escape is highly variable and depends on the strength of the immune
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response and the extent of immune dysregulation (87). Thus, the increasing
variability in the env gene observed in human infection after seroconversion has a
large component that is attributable to escape from immune pressure. In contrast,
the DKO-hu-HSC model appears to lack a robust adaptive immune response to HIV-
1 (3, 7, 94, 323). However, we observed similar rates of divergence and degrees of
diversity in comparing viral populations from infected human subjects and DKO-hu-
HSC mice. One interpretation is that the rates of divergence in DKO-hu-HSC mouse
and human infections, while similar, are driven by different selective pressures
acting on the population. For example, the virus is evolving either in response to
constant immune pressure or as a result of selection for more efficient Env function
in the absence of immune selection, as has been observed in cell culture (118, 143,
188, 192, 235), or perhaps also in the late stage of infection associated with
immunodeficiency. The emergence of the same amino acid substitutions in multiple
mice, particularly those that were linked to a phenotype such as enhanced CD4
binding or loss of glycosylation sites, was interpreted as evidence of positive
selection. Analysis of selection based on the relative rates of synonymous (dS) and
non-synonymous (dN) mutations across the V1-C5 region revealed no consistent
pattern. However, this type of analysis is compromised when too few synonymous or
non-synonymous mutations have accumulated to lend enough power to the analysis
or if only a few sites are under strong positive or negative selection. For this model
and over this period of time, the per-codon dN/dS rate ratio could not be reliably
determined because of a lack of mutations at synonymous sites.
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Some of the patterns of mutations were also similar to those observed in
humans, with most substitutions concentrated in the variable loops, and detection of
G-to-A hypermutations. However, evolution in this model is distinguished from
natural infection by the quality of some mutations that grew out in the population. We
observed that a number of Env variants isolated from several mice exhibited
increased sensitivity to V3-specific antibodies such as 447-52D, which has been
shown to be dependent on Env conformation and generally inactive against primary
isolates, presumably as a result of occlusion of the V3 epitope in the wild-type, non-
receptor-bound conformation of Env (13, 143). Specifically, we observed two
mutations in V2 that were selected in most mice and resulted in amino acid
substitutions I165R and D167N. We found that all of the viruses tested that evolved
neutralization sensitivity to 447-52D had one of these two substitutions and that
either of these alone, when reintroduced into the parental virus, HIV-1JRCSF,
rendered this virus more sensitive to neutralization. Variants with increased anti-V3
antibody sensitivity also exhibited increased resistance to competitive inhibition by
the anti-CD4 antibody Leu3a. This was interpreted as increased CD4 binding
efficiency.
Both 165R and 167N substitutions are represented at approximate
frequencies of 3% and 12%, respectively, in the HIV Sequence Database (Los
Alamos National Laboratories HIV Sequence database), whereas the most common
amino acids at these positions, I165 and D167, are both found at frequencies of
about 67%. These sites therefore exhibit some variability in human infections, and
substitutions at these sites, along with other mutations that affect Env conformation,
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may be markers of a loss of robust humoral immune pressure in late stage disease,
although a direct link has yet to be made in natural infections. These substitutions
have, however, been identified in several studies of virus passaged in cell culture
(188, 235, 270, 312). While all of these studies find one or both of these
substitutions to be linked to increased CD4 binding affinity (or sensitivity to CD4
mimics), the effects that these substitutions have on sensitivity to V3 antibodies in
particular vary with the genetic background and the presence of different co-evolving
substitutions. In our study, I165R/K and D167N appear to be mutually exclusive, and
their appearing together, or in combination with other substitutions, may alter their
neutralization phenotype. It is likely that these substitutions, along with others
observed in viruses that have been passaged in cell culture systems, represent
evolution toward heightened Env function through increased CD4 binding affinity or
evolution toward CD4 independence, in the absence of neutralizing antibodies, as
has been postulated previously (143, 192, 235). Further studies are required to
ascertain whether or not these types of mutations are selected in people during
profound immunosuppression and if they are linked to other phenotypes, such as
CXCR4 tropism, that appear in late stage disease.
We also observed an overall loss of specific PNLG sites in multiple mice.
Mutations that resulted in the loss of PNLG sites included sites that have been
demonstrated to be conserved or selected in a long term infection in a
Simian/Human Immunodeficiency Virus model (N339 and N386) (17). Other PNLG
sites that were lost have been identified as central in a network of coevolving PNLG
sites (N411) (231). The loss of the N386 site, which was observed at a high
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frequency in three mice, has been implicated in enhancing HIV-1 replication in
macrophage, which express low levels of CD4 and likely require changes in Env that
increase CD4 affinity in order to be infected efficiently (74). Thus, the observed
losses of N-linked glycosylation sites in mice, as with the changes affecting
neutralization to V3 antibodies, also might represent selection for changes in Env
that increase infectivity in the absence of neutralizing antibodies.
Another feature of natural HIV-1 infection is the emergence, usually late in
chronic infection, of variants that use CXCR4 as a co-receptor. This occurs in about
50% of individuals infected with subtype B HIV-1 (49, 144). While this phenotypic
switch in the population often coincides with a rapid drop in CD4+ T cell count and
disease progression (49), the selective pressures driving this switch are not clear. A
stochastic model where the appearance of X4 variants is limited by the chance
occurrence of the right combination of mutations does not explain their emergence in
humans where the host likely has also to be immunodeficient (103, 114, 144). In one
infected DKO-hu-HSC mouse we detected variants that could use CXCR4 as their
co-receptor in addition to CCR5. These variants had distinct V3 sequences that were
indicative of CXCR4 usage, and which were detected at weeks 43 and 44, but not at
week 40. Coincidentally, 3 days prior to the detection of X4 variants, Ontak
treatment (see Methods) was administered, which resulted in Treg depletion and
increased T cell activation. Ontak treatment may therefore have played a role in
creating an environment that potentiated X4 virus emergence in the periphery.
However, it is also likely that the X4 variant preexisted in the MLN, the tissue in
which it was found to be compartmentalized one week later. Only one of three mice
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treated with Ontak developed detectible X4 virus, and no other biological
characteristic of virus examined in this study could be attributed to an Ontak
treatment effect. Early steps in the evolution of CXCR4 tropism may require the
same conformational changes that render the virus sensitive to specific antibodies
(28). A small effective population size in these mice, compared to humans, could
also partly explain the emergence and outgrowth of X4 variants as following a
stochastic process (26, 250). Nonetheless, this animal model provides the
opportunity to explore further the link between X4 emergence and other Env
phenotypes that evolve in the absence of a robust immune response.
Examination of the tissue distribution of variants in the mouse in which the X4
virus emerged showed that 95% of variants in the MLN were X4 compared to 15% in
the peripheral blood and 22% in the spleen. While it is possible that apparent
compartmentalization of X4 variants in the MLN was a result of chance seeding,
there may also be a selective advantage for X4 viruses in this compartment.
Previous studies have identified the thymus as a likely environment for X4 virus
selection due to the high levels of CXCR4 expressed on resident T cells (257). In
contrast, the MLN in wild type mice is responsible for linking both inductive and
effector sites of the gut-associated lymphoid tissue (GALT), such as Peyer’s Patches
and the lamina propria and mucosal epithelium. As such, MLNs normally harbor a
large population of activated T cells, predominantly with a memory phenotype,
expressing high levels of CCR5. It is the large number of activated CD4+ CCR5+ T
cells found in the GALT that are thought to support establishment and high levels of
replication of the CCR5-tropic viruses responsible for initial infection. Indeed, this
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tissue is decimated during peak viremia in the acute stage of infection (98, 163).
Thus it is unclear how CXCR4-tropic viruses would have an advantage in this
environment under normal conditions. However, the MNL in this model, populated by
human T cells, may represent a different environment than that seen in normal
humans or wild-type mice. The GALT has been shown to be underdeveloped in this
model (116) indicating that the MLN may not be populated by the same CD4+ T cell
subsets present in this tissue in a normal individual. Further exploration is required
to assess more fully the cellular subsets populating this and other compartments in
this model and the effect they have on the selection of viruses with different
phenotypes.
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aMice were reconstituted with one of two CD34+ HSC donors, A or B.
bPercentage of cells expressing human CD45 in the peripheral blood
determined at 11.5 weeks after hCD34+  transplantation.
cThe harmonic mean ratio of CD4+ to CD8+ T cells in the peripheral blood of 2
samplings prior to infection.
dRatio of CD4+ to CD8+ T cells in the peripheral blood at  termination: 44 weeks
for mice 5-8 and 22 weeks for mice 64 and 67.
Mouse
HSC 
Donora
PB 
%hCD45+b
CD4/CD8 pre-
infectionc
CD4/CD8 at 
terminationd
5 A 9.3 14.69 6.833
6 A 15.1 6.67 0.579
7 A 7.9 4.18 0.317
8 A 15.9 10.91 0.006
64 B 23.7 1.35 0.039
67 B 9.8 1.51 0.263
Table 3.1: Immune reconstitution and CD4+ T cell depletion
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aFirst position in clone name indicates mouse number or parental
clone for mutants.
bIC50 values were obtained from a sigmoidal dose-response curve
fitted to 8-10 concentration data points  (3 replicates per data point)
ranging from  2 to 10-4 ug/ml.
cIC50 values were obtained from a linear curve fitted to 3
concentration data points  at 10, 1 and 0.1 ug/ml as presented in Figure 5.
Table 3.2: Resistance to anti-CD4 antibody inhibition
Clonea
Leu3a (95% CI) 
(ng/ml)b 447-52D (ug/ml)c
6_38 40.9 (34.7 - 48.2) <0.1
6_39 43.2 (39.3 - 47.6) <0.1
JRCSF I165K 35.3 (31.0 - 40.2) 0.2
JRCSF D167N 33.0 (29.4 - 37.1) 1.4
7_16 23.2 (19.3 - 27.7) >10
7_25 23.0 (19.6 - 27.1) >10
JRCSF 23.5 (19.8 - 28.0) >10
IC50 
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Figure 3.1. Plasma viral load over 44 weeks of infection for mice 5-8. The DKO-hu-
HSC mice were infected intravenously with HIV-1JRCSF. HIV-1 viremia in plasma
samples (copies/ml) from all infected DKO-hu-HSC mice were measured at 3, 10,
22, 40, and 44 weeks post infection for mice 5-8 and 4 and 22 weeks post infection
for mice 64 and 67.
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Figure 3.2. Phylogeny of HIV-1 sequences from all mice. Maximum likelihood
tree of V1-C5 sequences from the peripheral blood (PB) at week 44 for mice 5-8
and week 22 for mice 64 and 67. Symbols at branch tips indicate mouse number.
Open square: mouse 5; open triangle: mouse 6; closed triangle: mouse 7;
diamond: mouse 8; closed circle: mouse 64; closed square: mouse 67. The open
circle at the top of the tree indicates the JRCSF input sequence. Asterisks
indicate bootstrap values >70%. Scale bar indicates substitutions per site.
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Figure 3.3. Comparison of divergence rate and diversity in mouse and humans.
Distance measurements were based on branch lengths of maximum likelihood trees.
Symbols in the Mouse group in A and B indicate the mouse number, as in figure 2.
Open square: mouse 5; open triangle: mouse 6; closed triangle: mouse 7; diamond:
mouse 8; closed circle: mouse 64; closed square: mouse 67. A) Divergence rates in
mice and in human cohorts initially sampled post-seroconversion (“Human post-
seroconversion” in A and B) (Shankarappa et al. 1999 ) and pre-seroconversion
(“Human pre-to-post seroconversion” in A and B) (Salazar Gonzales et al. 2009) was
measured for the C2-V5 region of env. For the post-seroconversion dataset, mean
distance, based on branch lengths of a maximum likelihood tree, was measured
from the consensus at a time point 3-5 months post-seroconversion for variants
sampled at time points 9-24 months later. Sequences sampled at the first time point
were relatively homogeneous but for 2 subjects which were likely infected with 2
variants and which were removed from the analysis. For the pre-to-post-
seroconversion dataset, mean distance was measured from the consensus at time
points estimated to be 20-24 days post infection, 9-16 days prior to seroconversion,
for variants sampled 3-19 months later. Mean distance was divided by the time
between sampling time-points to obtain rates of divergence. In mice, mean distance
was measured from HIV-1JRCSF for variants sampled at the last time point, either 22
or 44 weeks post infection. B) Population diversity is represented as the mean
pairwise distances within populations at or extrapolated to 44 weeks post infection,
for mouse and pre-to-post-seroconversion human samples, or post-seroconversion
for the post-seroconversion human samples. A Student’s t-Test was used to
determine  P-values for differences between distributions. P-values for all
comparisons were >0.2.
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Figure 3.4. Positions and classifications of amino acid substitutions in the V1-C5
region of Env. Amino acid numbering on the abscissa corresponds to the HXB2
reference sequence. Bars on the graph indicate positions of substitutions and the
frequency with which substitutions were identified in a mouse population at 44
weeks post-infection. Variable loops are shaded in grey. Substitution types are
indicated by symbols. Square: addition of a PNLG site; diamond: loss of PNLG site;
open triangle: >95% sequence conservation in subtype B; closed circle: component
of the CD4 binding domain; asterisk: reversion to subtype B consensus; closed
triangle: linked to co-receptor tropism. Substitutions at positions 165 and 167 that
affected Env conformation and substitutions identified in 3 or more mice are
indicated along with their mean percent abundance in the population. Substitutions
identified in both donor sets are indicated by “AB” (see Table 1). “TC” indicates
substitutions associated with tissue culture adaptation in other studies. Assessment
of >95% sequence conservation was based on a random sampling of 300
sequences (one per patient) from the Los Alamos HIV Sequence Database.
Sequencing of 30 SGA amplicons from the inoculum revealed 4 single point
mutations among 3 amplicons. One of these mutations, at codon 151, was observed
later in infection in mouse 67.
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Figure 3.5. Neutralization sensitivities to 447-52D of selected envelope clones and
mutants. A) Clone names identify the mouse followed by the clone number (e.g.
5_10). Percent inhibition is indicated for 447-52D antibody concentrations from 10-
0.1 ug/ml. Error bars represent the range of 2 replicates. SF162c: a neutralization
sensitive chimeric env in which the V3 region of HIV-1SF162 was replaced with the V3
loop from HIV-1JRFL (Patel 2008). B) Alignment of the V2 loop of clones tested for
neutralization sensitivity to 447-52D. Positions 165 and 167 are indicated. C)
Neutralization sensitivity of HIV-1JRCSF with substitutions I165R, D167N or I165K
alone.
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Figure 3.6. Phenotypic analysis of coreceptor tropism. A) Relative CXCR4 and
CCR5 activity of env clones from 4 mice at week 44 post-infection in a pseudotype
entry assay using U87.CD4 cells expressing either CXCR4 or CCR5. env clones
exhibiting X4 usage are boxed and labeled “dual tropic”. Error bars represent the
standard deviation of 3 replicates. These data are representative of multiple tropism
assays. B) Alignment of the V3 loops of env clones tested in 6A. Clone names
indicate mouse, tissue origin (peripheral blood - PB) and clone number. Env proteins
exhibiting X4 tropism, boxed in 6A and indicated as “dual tropic”, are indicated in the
alignment as those with changes in their V3 loops at positions 11 and 25 associated
with the ability to use CXCR4. These variants were identified only in mouse 6 and
comprised 15% of the population.
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Figure 3.7. Maximum likelihood phylogeny of env variants (V1-C5) recovered from
different tissue compartments in mouse 6. Bootstrap values >80% and >50% are
indicated by double and single asterisks at nodes, respectively.  Sequences were
derived from viral DNA except in the case of sequences from the peripheral blood,
which were from plasma viral RNA. The tissue of origin of sequences is indicated by
symbols. Triangle: spleen; diamond: bone marrow; square: peripheral blood; closed
circle: mesenteric lymph node. An open circle indicates the JRCSF input sequence.
The boxed cluster indicates X4-like V3 sequences, which contain substitutions at
positions 11 and 25 in addition to others and cluster together. A subset of these
sequences was phenotypically tested to confirm tropism. Of the variants in the MLN,
95% contained an X4-like V3 sequence, indicating compartmentalization of this
phenotype in this tissue in mouse 6 (p<0.0001).
Chapter 4
Forces Shaping Evolution In Late Stage Disease Contribute To The Evolution
Of CXCR4 Tropism And May Contribute To Macrophage Tropism
The following individuals contributed to experiments presented in Chapter 4:
Kathryn Arrildt assisted with the generation of Env mutants and Sarah Joseph
assisted with the entry assays using Affinofile cells.
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4.1 ABSTRACT
I previously found that the Env protein of the CCR5- tropic HIV-1 isolate
JRCSF evolved a more open conformation and increased CD4 binding affinity in a
humanized mouse model of HIV-1 infection that lacked a strong HIV-1 antibody
response. Within the context of this CCR5-tropic “background” phenotype, variants
emerged that could efficiently use CXCR4 as their coreceptor. In this study, I further
characterized the background R5 phenotype with regard to Env conformation, the
ability to infect cells expressing low levels of CD4 and CCR5, mimicking
macrophage, and infectivity using only CXCR4. I found that the background R5
phenotype included the ability to use low levels of CD4 and low level, but
measurable, infectivity using CXCR4, compared to the parental virus JRCSF. I found
that the major contributors to this phenotype were substitutions in the V2 loop that
were linked to conformational changes, and I identified a similar pattern of
substitutions in viruses from humans who were immunosuppressed and at risk of
having CXCR4-tropic variants. These data are consistent with the hypothesis that
specific conformational changes that are controlled by the conserved regions of the
V2 loop and are constrained by adaptation to the humoral immune response,
increase CD4 binding and promiscuous co-receptor usage and precede evolution of
CXCR4 variants in the absence of strong humoral immune selective pressures.
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4.2 INTRODUCTION
Defining the changes in the selective pressures that shape the evolution of
HIV-1 envelope glycoprotein phenotypes during late stage disease is critical to
understanding the environmental constraints placed on Env structures and
functions that may affect viral pathogenesis and escape from pharmacological
interventions directed at Env. Viral Env mediates entry into the host cell by
sequential binding of the primary receptor CD4 and a coreceptor, either of two 7-
transmembrane chemokine receptors, CCR5 or CXCR4. CXCR4-tropic (X4)
viruses are rarely transmitted and HIV-1 infection is usually established by
variants that require CCR5 as their coreceptor (R5 virus), a phenotype that
typically dominates early infection (134). In about one-half of individuals infected
with HIV-1 subtype B, a declining CD4+ T cell count marking late stage disease
coincides with the emergence of viral variants that can efficiently use CXCR4 as
a co-receptor (15, 48, 49, 244, 282). The primary genetic determinant of CXCR4
tropism is the composition of the relatively conserved (compared to the other
variable loops) ~35 amino acid variable loop 3 (V3), a structural component of
the coreceptor binding site in the gp120 subunit of Env, which determines co-
receptor specificity through specific interactions with the extracellular loops of
either CXCR4 or CCR5 (39, 50, 129). The reasons for the emergence of this new
Env phenotype, and its link to disease progression, are not well understood.
As discussed in Chapter 2, X4 variants emerge as a clonal outgrowth of
the preexisting R5 viral population and while these viruses are typically dual-
tropic in tissue culture assays, they may be dependant on CXCR4 in vivo (318).
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X4 variants also often continue to co-exist with R5 variants in the peripheral
blood and show some degree of genetic mixing with R5 variants. X4 variants are
not highly compartmentalized in separate anatomical or cellular niches, and it is
not clear that X4 variants necessarily replace the existing R5 population. This
apparent overlap in the X4 and R5 populations could indicate that strong niche
selection itself is not required for X4 maintenance, even if it is in emergence.
While the selective pressures that drive (or select against) CXCR4 tropism
are not clear, several hypotheses have been proposed. Changes in the relative
numbers of target cells expressing CCR5 and CXCR4 may select for CXCR4
tropism in late stage disease as a result of CCR5+ CXCR4+ memory T-cell
depletion over the course of infection leaving a larger proportion of CCR5-
CXCR4+ naïve T cells which are vulnerable only to CXCR4 tropic virus (241).
However, memory T cells express both CCR5 and CXCR4 and CXCR4+ CCR5-
naïve T cells are abundant in healthy individuals. Importantly, in resistance
selection experiments using viral inhibitors directed at CCR5 that block Env
interactions with this coreceptor, inhibition more often selects for variants that
can use inhibitor-bound CCR5 rather than for coreceptor switching (236, 286). In
vivo, CCR5 inhibitors select pre-existing, but previously undetected minor X4
variants rather than de novo X4 variants, and once CCR5 inhibition is removed,
R5 viruses regain dominance (reviewed in Kuritzkes 2009 (155)). As few as 2
mutations, are sufficient to confer X4 tropism (see below), a genetic barrier that is
likely lower than resistance to many other inhibitors, if not CCR5 inhibitors
themselves, indicating that CXCR4 variants are strongly selected against in
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earlier stages of disease. This observation is consistent with the hypothesis that
CXCR4-tropic variants evolve, perhaps to exploit CXCR4 on both memory and
naïve T cells, only when released from immune selection constraints that exist in
immunocompetent individuals.
X4 variants may be more susceptible to immune surveillance. It has been
observed that X4 viruses are preferentially suppressed by a CTL response when
Rhesus macaques are co-infected with X4 and R5 variants (103). It has also
been found that emergent X4 variants in late stage human infection are more
sensitive to neutralization by antibody specificities that suggest structural
changes that expose otherwise cryptic epitopes, such as the CD4 binding site
and the V3 loop (29, 114, 169). In Chapter 3, I found that in the environment of
the humanized mouse, which did not exhibit a strong humoral response to HIV-1,
the CCR5-tropic JRCSF isolate evolved to become highly sensitive to V3-specific
antibody neutralization and exhibited increased CD4 binding affinity and that
within this phenotypic background, X4 variants emerged. In the following study, I
provide some additional evidence to support the hypothesis that structural
changes that are required to evolve CXCR4 tropism render the virus more
sensitive to immune selection. These structural changes allow increased CD4
binding and exposure of the V3 loop, which allow more promiscuous co-receptor
usage and eventual evolution, based on V3 specificity, of efficient CXCR4 usage.
Below, I further define the structural and phenotypic changes that occur on the
path towards CXCR4 tropism in a virus that evolved in the absence of strong
humoral immune pressure in the humanized mouse (mouse-adapted) and
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attempt to link these genetic changes to changes observed in HIV-1 sequences
from immunosuppressed humans.
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4.3 MATERIALS AND  METHODS
4.3.1 Cloning and mutagenesis of env genes.
As described in Chapter 3, env clone expression vectors were generated
from selected SGA amplicons amplified from plasma viral RNA of mouse-
adapted HIV-1 using the pcDNA3.1 Directional TOPO Expression kit (Invitrogen,
Carlsbad, CA). Mutations in the wild-type JRCSF env were introduced by way of
PCR re-synthesis of the JRCSF env expression vector using primers containing
the desired base change (294).
4.3.2 Pseudovirus entry assays.
Generation of pseudotyped virus and pseudovirus phenotyping assays
were carried out as described in Chapter 3. 293T cells were co-transfected with
env expression vectors and the pNL4-3.Luc.R-E- luciferase reporter vector (109)
(obtained from ARRRP) using the Fugene transfection reagent (Roche,
Mannheim, Germany) according to the manufacturer’s protocol to generate
pseudovirus. Cells were washed with phosphate buffered saline 8-12 hours after
transfection in order to reduce transfection complex carry-over and background
luciferase expression in target cells, which was monitored with an env-negative
control. Virus supernatant was collected 48 hours after transfection.
Co-receptor phenotype was determined based on detection of luciferase
activity in U87.CD4+ cells expressing either CCR5 or CXCR4 (14) (obtained from
ARRRP) using the Luciferase Assay System kit (Promega, Madison, WI).
Pseudovirus was incubated with U87.CD4.CXCR4/CCR5 cells for 36-48 hours
prior to lysis of cells and measurement of luciferase activity. Co-receptor-
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dependent viral entry was confirmed using inhibitory concentrations of AMD3100
(112) (CXCR4 inhibitor) or TAK-779 (6) (CCR5 inhibitor) (both obtained from
ARRRP).
Sensitivity to neutralization by the antibody b12 (32) (obtained from
ARRRP), 4E10 (278) (obtained from ARRRP), 2G12 (27) (obtained from
ARRRP) and the anti-V3 antibodies 447-52D (46) (obtained from ARRRP) and
19b (264) and 2.1E (gifts from Dr. James E. Robinson) was assessed on
U87.CD4.CCR5 and TZM-BL cells (obtained from ARRRP), which are permissive
to X4 and R5 viruses and contain an integrated, Tat-responsive luciferase
cassette (65, 226). Sensitivity to the anti-CD4 antibody Leu3a (CD4 Pure) (BD
Biosciences, San Jose, CA) was assessed on U87.CD4.CCR5 cells.
The ability of pseudovirus to infect cells expressing low levels of CD4 and
CCR5 was assessed on Affinofile cells, transgenic 293T cells which express CD4
and CCR5 from independent inducible promoters (132). Cells were maintained in
Dulbecco’s Modified Eagle Medium containing 10% dialyzed Fetal Bovine Serum
(2-14kD dialyzed; Atlanta Biologics) and 50 ug/ml blastocidin (D10F/B). Cells
were seeded in poly-L-lysine-treated 96 well plates with 2.5x105 cells/well.
Twenty-four hours after seeding, CD4 and CCR5 expression was differentially
induced with the addition of tetracycline and ponasterone A, respectively. CD4
expression was induced at 6 levels (0-0.1 ug/ml tetracycline) and CCR5 at 4
levels (0-0.93 uM/ml ponasterone A) for a total of 24 induction levels. Eighteen
hours later, the induction medium was removed and cells were spinoculated with
pseudovirus or prepared for flow cytometry to measure induced CD4 and CCR5
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densities. Cells were prepared for flow cytometry by staining at room temperature
for 30 minutes with either phycoerythin (PE)-conjugated anti-human CD4
antibody (clone Q4120, BD Biosciences) or PE-conjugated mouse anti-human
CCR5 antibody (clone 2D7, BD Biosciences). Cells were then fixed with 4%
paraformaldehyde, washed and analyzed. CD4 and CCR5 levels were quantified
using QuantiBRITE beads as a standard (BD Biosciences).
Analysis of neutralization activity in sera from HIV-1 infected subjects was
assessed as follows. Sera or plasma was obtained from subjects from the
cohorts described above. Neutralization assays were performed as previously
described (189). An env-negative HIV-1 drug-resistant backbone (pNLCH-
luciferase env- clone 1617 + K103N) was pseudotyped with wild type JRCSF or
the antibody-sensitive mouse-adapted JRCSF 6-39 Env clone. Neutralization
titers of sera were determined on TZM-BL cells in triplicate and the average
relative infectivity determined.
4.3.3 Analysis of HIV-1 sequences from human subjects.
A total of 534 sequences were obtained by single genome amplification of
viral RNA from the plasma of 33 subjects with CD4+ T cell counts ranging from 0
to 823 cells/ul. Sequences from eighteen chronically infected subjects with CD4+
T cell counts ranging from 241 to 823 cell/ul were from CHAVI-001 described
previously (134). Sequences from 15 subjects with low CD4+ T cell counts,
ranging from 0 to 233 cells/ul, were amplified from excess tissue obtained from
the baseline blood draw of subjects participating in the virology sub-study of a
ritonavir efficacy trial described previously (35) or from baseline blood draws of
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subjects entering ACTG 359 described elsewhere (100). Potential N-linked
glycosylation sites (PNGL) were predicted using N-Glycosite which infers a
PNLG site in NXT/S motifs where X≠P (325) and was accessed through the Los
Alamos National Laboratories HIV-1 Database website
(http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html ).
4.3.4 Signature amino acid sequence analysis.
All sequences from 33 subjects were aligned in MAFFT (133)  with manual
editing of the alignment. One sequence per patient was sampled 5 times without
replacement. Aligned sequences were then separated into high and low CD4+ T
cell count groups. The amino acid frequency and statistical significance of
frequency associations at each position for each sample set was determined
using VESPA (147) accessed through the Los Alamos National Laboratories
HIV-1 Database website
http://www.hiv.lanl.gov/content/sequence/VESPA/vespa.html. The purpose of this
analysis was to screen for positions that might be relevant to either the high or
low CD4 environments; however, too few subjects’ virus populations have been
acquired thus far to power this analysis properly. The Bonferroni-corrected α of
0.00006 for differences at a given position was not met at any position in any of
the five sequence sampling sets, although some positions did approach
significance in >3 of 5 sequence samplings. Those observations are discussed in
the results.
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4.4 RESULTS
4.4.1 Previous observations
In Chapter 3, when variants from mouse 6 were screened for their
sensitivity to antibodies directed at a conserved epitope in V3, I found that all
clones tested, including those with an X4 phenotype, were >1000 fold more
sensitive than the JRCSF parental virus to V3 antibodies (Figure 3.5 and Table
4.1), indicating the presence of a major structural change that had exposed the
V3 loop in these variants. This was in contrast to the phenotypes of most primary
isolates which are typically resistant to V3 antibodies (13), presumably due to
structural masking of the V3 epitope, which is only exposed upon CD4 binding to
allow interaction with the extracellular loops of the co-receptor.  I found that either
of two mutually exclusive amino acid substitutions in V2, I165R or D167N, was
responsible for a large component of this phenotype (Figure 3.5, Table 4.1). I
also showed that these V3 antibody-neutralization phenotypes correlated with
increased resistance to an anti-CD4 antibody indicating increased CD4 binding
affinity (Table 3.1 and Table 4.1). A subset of these Env variants in mouse 6
acquired the ability to efficiently use CXCR4, a specificity that was predominantly
conferred by changes in the V3 loop. The specific changes distinguishing the X4
variant from the parental virus JRCSF were S5N, S11G, F20I and E25K (V3
numbering) (Figure 3.6), although the minimum combination of substitutions
needed was not assessed. All but S5N were unique to X4 variants. In the present
study, I followed up these observations with additional analyses of selected
mouse-adapted clones and mutants (Table 4.1). I further defined the V3
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mutations that are required for the X4 phenotype. I assessed sensitivities of
these Envs to other monoclonal antibodies in order to further define the structural
changes in these Envs. I then linked these structural changes to the ability to use
low levels of CD4, and I mapped the phenotypic progression of CXCR4 usage in
relation to the other phenotypes observed for these clones and mutants.
4.4.2 Mutations in V3 that confer strong X4 tropism
I determined the effect that different combinations of the V3 mutations
identified in the X4 virus from mouse 6 had on entry of Env-pseudotyped virus in
cells expressing CD4 and either CXCR4 (U87.CD4.CXCR4) or CCR5
(U87.CD4.CCR5) (Figure 4.1). S5N represents a reversion to the subtype B
consensus and was present in over 90% of the variants sampled from mouse 6,
which included the majority of variants that did not exhibit any other V3
substitution. S5N alone showed a modest but significant increase in the ability to
infect CXCR4-expressing cells (CXCR4 infectivity), over 10-fold that of JRCSF. I
also found that while the basic residue at position 25 is often the strongest
predictor of an X4 virus in other studies (117, 129), CXCR4 infectivity  was
increased less than 2-fold that of JRCSF, although the overall infectivity of virus
prepared with this Env mutant was greatly decreased. Addition of the S11G
substitution to the E25K substitution conferred a significant increase in CXCR4
infectivity. Addition of the F20I to S11G and E25K increased CXCR4 infectivity
further. When S11G was removed from the full set of mutations, leaving only
S5N, F20I, and E25K, both absolute CXCR4 infectivity, and CXCR4 infectivity
relative to CCR5 infectivity was maintained indicating that either F20I or S5N
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plays a critical role in X4 tropism in this Env background. Interestingly, all V3
mutants, except for E25K alone, appeared to have minimal deficiencies in the
ability to use CCR5 in these cells, although all 4 mutations together, S5N, S11G,
F20I and E25K, conferred the highest level of both CXCR4 and CCR5 infectivity,
but CXCR4 infectivity was relatively greater than CCR5 infectivity. Importantly,
virus pseudotyped with X4 Env clones 6-45 and 6-60, isolated from the mouse 6
virus population exhibited nearly a 10-fold increase in CXCR4 infectivity relative
to their CCR5 infectivity, whereas virus with changes only in V3 exhibited less
CXCR4 infectivity as a proportion of CCR5 infectivity, indicating that in addition to
mutations in V3, other mutations in these Env clones contribute to a stronger X4
phenotype.
4.4.3 Effect of mutations in gp120 on Env structure and antibody
neutralization sensitivity.
In order to further characterize this structural change in gp120 indicated by
increased sensitivity to V3 antibodies, I assessed the sensitivity of the selected
mouse-adapted env clones and mutants listed in Table 4.1 to other antibodies to
determine if sensitivity to V3 antibodies represented a global increase in
neutralization sensitivity unrelated to specific structural changes. I found that the
patterns of sensitivity to the broadly neutralizing antibody 4E10, which targets an
epitope at the membrane proximal region of gp41, was uniform across clones,
and sensitivity to 2G12, which targets specific glycans on gp120 correlated with
the absence of specific glycan epitopes (in Env 6-39), but not with V3 antibody
neutralization, indicating that antibody inhibition was a result of specific structural
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changes in gp120 and not a general effect of reduced Env expression or virion
loading, or another mechanisms unrelated to specific structural changes (Table
4.1).
In order to further define this structural rearrangement, I tested these env
clones for their sensitivity to b12, an antibody directed at a conformational
epitope overlapping the CD4 binding site. b12 is unique in its ability to access the
conserved epitopes in the CD4 binding site that are otherwise obscured due to
occlusion or conformational flexibility (327). b12 possesses an elongated CDR
H3 loop that may be able to penetrate into the CD4 binding pocket to access and
make more contacts with conserved residues (327). CD4 binding, on the other
hand, requires increased avidity to counteract a relatively weak initial interaction
between CD4 and the CD4 binding loop in gp120(327). While most primary
isolates are sensitive to b12 to begin with, increased sensitivity to b12 has been
shown to correlate with soluble CD4 sensitivity and increased CD4 binding
affinity (72) and likely indicates a conformational change in the CD4 binding site,
perhaps locking gp120 into a more CD4-accessible, and therefore more b12-
sensitive form. Indeed, the mouse-adapted Envs 6-39 and 6-38, which were
highly V3 antibody-sensitive and showed increased CD4 binding, were also
increased in their sensitivity to b12. However, neither the I165R nor the D167N
mutants displayed a measurable increase in b12 sensitivity (Table 4.1).
Another mutation, a loss of a glycosylation site at position 386 near the
CD4 binding site, was also observed in nearly all mouse-adapted Envs from
mouse 6, except those with X4 V3 genotypes, and this loss has been shown to
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increase CD4 binding as well as b12 sensitivity (74). While I did not observe an
increase in V3 antibody sensitivity or CD4 binding of the N386K mutant in
JRCSF, I measured a small increase in b12 sensitivity, less than that measured
for the highly V3 antibody-sensitive clones 6-38 and 6-39, indicating that this
mutation acts specifically in the b12 interaction and that its effect on CD4 binding
is at most subtle (Table 4.1). Furthermore, unlike the V2 mutations, it is absent in
the background of env sequences with X4 V3s, indicating that it is not directly
involved in the evolution of co-receptor tropism. The common feature that is
found in both R5 and X4 mouse-adapted virus is the presence of mutations that
both expose V3 and impact the structure of the CD4 binding site.
4.4.4 Env structural changes that expose V3 increase viral entry on cells
when CD4 is limiting.
Increased CD4 binding is typically associated with macrophage tropism as
it allows virus to utilize the low levels of CD4 and CCR5 expressed on
macrophage. I was therefore interested in determining if this was a characteristic
of the structurally evolved mouse-adapted X4 or R5 Envs and single V2 mutants
that exhibited V3 antibody sensitivity and/or increased CD4 binding.
In order to assess the ability of env clones to mediate entry at limiting
levels of CD4 and CCR5, viral infectivity was measured on 293T cells expressing
different levels of CD4 and CCR5 (Affinofile cells) (132) for JRCSF wt, JRCSF
with the I165R V2 mutation, mouse-adapted R5 clone 6-39, and mouse-adapted
X4 clone 6-60 (Figure 4.2). Viral infectivity increased with both CD4 and CCR5
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levels but was significantly more dependent on CD4 than CCR5 for all viruses
tested (Figure 4.2 A-C).
Comparison of infectivity at low CD4 and low CCR5 levels, as a
percentage of infectivity on cells expressing the maximum level of CD4,
demonstrated a significant increase in entry of variants containing the V2
mutations affecting V3 exposure. The single substitution I165R, which is a
phenocopy and mutually exclusive of D167N, alone conferred increased entry on
low CD4/low CCR5 cells compared to JRCSF. Mouse-adapted clone 6-39 differs
from JRCSF between V1 and C5 by 10 amino acid substitutions, including one
substitution in V3, S5N, and the D167N substitution in V2, and showed a
increase in relative infectivity on low CD4/CCR5 cells similar to that observed for
the I165R single mutant. This was in spite of the observation that 6-39 Env
showed greater CD4 binding affinity and sensitivity to V3 antibodies than the
I165R mutant (Table 4.1). Mouse-adapted clone 6-60, which encodes an X4 Env,
showed a significantly greater relative infectivity on CD4/CCR5 low cells
compared to all other clones. The cells used in this assay express endogenous
CXCR4, which may account for the increased infectivity of the 6-60 X4 clone,
although, at low CD4, increasing CCR5 did not appear to increase infectivity
appreciably for any Env. 6-60 differs from JRCSF by 7 substitutions in the V1-C5
region, including the 4 mutations in V3 (S5N, S11G, F20I, E25K) and the D167N
substitution in V2. 6-60 differs from 6-39 by 7 substitutions, 6 that are absent in
6-60 and 1 that is present in 6-60, but absent in 6-39 (T202R).
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The 6-39(R5) and 6-60(X4) Envs have 3 substitutions in common:
I165R/D167N, S5N (V3), and the loss of an N-linked glycosylation site at position
411, at the base the V4 loop. As discussed in Chapter 3, the I165R/K/D167N
mutation set was tightly linked to the loss of a glycosylation site at position 411,
which was absent in virtually all clones that contained either I165R or D167N.
Introduction of this mutation in combination with 165R had no effect on relative
infectivity in low CD4/CCR5 cells (data not shown), as might be expected based
on the similar infectivity of the single I165R mutant and 6-39, which contains both
mutations; the significance of the loss of the glycan at position 411 requires
further investigation.
In summary, the single substitution at position 165 was able to increase
relative infectivity at low CD4 levels compared to JRCSF. The additional
mutations in 6-39, which contributed to increased CD4 binding affinity, as
measured by Leu3a resistance, and b12 sensitivity, did not increase infectivity at
low CD4 and CCR5 concentrations compared to the I165R mutant alone,
highlighting the importance of I165R, and by extension D167N, in conferring this
specific phenotype.
4.4.5 Effect on relative CXCR4 usage of mutations external to V3.
I have shown thus far that the mutations that accumulate in mouse-
adapted Env clones, increased sensitivity to V3 (19b, 447-52D, 2.1E) and CD4
binding site (b12) antibodies, increased CD4 binding and, separately, increased
the ability to use low levels of CD4 and CCR5. Sensitivity to V3 antibodies in
particular, which was the most common feature of mouse-adapted Envs (Chapter
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3), indicates a more open conformation of Env that increases V3 exposure and
plays a role in enhancing entry into cells expressing low levels of CD4 and
CCR5.
I hypothesized that these features of Env, which evolved prior to the
emergence of X4 tropism conferred by changes in V3, represent prerequisite or
intermediate features of X4 tropism. If so, they might confer some level of X4
tropism, as has been observed in primary isolates that lack strong V3-driven X4
tropism but show low-level infectivity on cells expressing only CD4 and CXCR4
(CXCR4 infectivity), compared to their infectivity on cells expressing only CD4
and CCR5 (CCR5 infectivity) (84, 121). I therefore determined infectivity of Env
mutants and mouse-adapted clones on U87.CD4.CXCR4 cells and compared
this to infectivity on U87.CD4.CCR5 cells.
Relative CXCR4 and CCR5 infectivities are shown in Figure 4.3 for Env
clones exhibiting a range of V3 antibody sensitivities and CD4 affinities. Mutant
(I165R or D167N) and mouse-adapted Env clones with R5-like V3 loops, 6-38
and 6-39, showed significant and progressive increases in CXCR4 infectivity,
relative to CCR5 infectivity, that correlated with sensitivity to V3 antibody and
CD4 binding. Envs 6-38 and 6-39, which showed increased CXCR4 infectivity
compared to the single mutants I165R and D167N, also contained the S5N
mutation in V3, which was shown to confer low level X4 tropism alone (Figure
4.1). Clones with X4-like V3 loops (6-60 and NL4-3, a prototypical X4 virus) (V3
geno. In Figure 4.3) exhibited at least ten-fold greater CXCR4 infectivity than
clones with R5-like V3 loops. Env clones with R5-like V3 loops that displayed the
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highest activity on U87.CD4.CXCR4 cells (6-38 and 6-39) exhibited greater
resistance to AMD3100, a small molecule antagonist of CXCR4, compared to
variants with X4-like V3 loops (Figure 4.3c).
The curve of increasing X4 activity appeared to have multiple phases
(Figure 4.3b). The single mutations I165R and D167N increased CXCR4
infectivity by nearly ten-fold compared to JRCSF, but without an increase in
CCR5 infectivity. Mouse-adapted clones 6-38 and 6-39, which showed higher
sensitivity to V3 antibodies and increased CD4 binding compared to the single
mutants I165R and D167N, exhibited equal increases in both CXCR4 and CCR5
infectivity, perhaps illustrating an overall increase in infectivity regardless of co-
receptor use. The presence of an X4-like V3 in 6-60 was associated with a ten-
fold increase in CXCR4 infectivity over the R5 clones 6-39 and 6-39, but also a
decrease in the ability to use CCR5 by nearly the same magnitude. Thus in these
data, it appears that variants with R5-like V3 loops but with more open
conformations and increased V3 exposure, acquire the ability to infect, at a low
level, cells bearing only CXCR4 and CD4  (I165R and D167N). Increasing CD4
binding affinity may enhance this effect (6-38 and 6-39) by compensating further
for the weak interaction with CXCR4, which creates an evolutionary path for
further changes in V3 to enhance interaction with CXCR4; the acquisition of
these V3 changes likely diminishes the ability of V3 to interact with CCR5. This
pathway may only be initiated by the absence of an antibody response, perhaps
specifically a loss of antibodies targeted to V3 that would otherwise select for a
closed Env conformation.
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4.4.6 Sequence analysis of gp120 from HIV-1-infected subjects with high
and low CD4+ T cell counts.
The phenotypes that I observed in this study likely depended on the
absence of humoral immune pressure, based on previous studies also linking
these phenotypes, as well as some of these specific mutations, to passage in
tissue culture and therefore in the absence of immune selective pressures
(discussed in Chapter 3). I therefore wanted to know if any of the mutational
patterns identified in mouse-adapted isolates were present in HIV-1 populations
from human subjects with low CD4+ T cell counts, compared to populations from
subjects with relatively high CD4+ T cell counts, with the assumption that
immune selective pressures would be weaker when CD4+ T cell counts are low.
A total of 33 subjects with a range of CD4+ T cell counts were divided into low
and high CD4+ T cell count groups (low CD4 and high CD4, respectively). For
the 15 subjects in the high CD4 group, CD4+ T cell counts (cells/ul) ranged from
241 to 823, with a median of 382. For the 18 subjects in the low CD4 group,
counts ranged between 0 and 233, with a median of 93. For each subject,
between 7 and 27 viral genomes encompassing V2-V4 were amplified using
SGA (as described in chapter 2). X4 variants were inferred (by PSSM) to be
present in 15 of the 18 subjects with low CD4+ T cell counts and in 1 of the 15
subjects with high CD4+ T cell counts; these variants represented less than 50%
of the population in most cases. Analyses were carried out to determine if there
were any positions at which amino acid substitutions were disproportionately
represented in the low versus the high CD4 groups. The average number of
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glycosylation sites, sequence length, and V2 charge were also compared
between low and high CD4 groups.
Analysis of the differences in amino acid substitutions in HIV-1 populations
between groups was carried out by sampling one sequence per patient multiple
times without replacement. While this analysis was not powered to detect
differences on a sequence-wide basis, several positions approached
significance. Only one position in V3, 319 (V3 position 22) with a T to an A
substitution, approached significant enrichment in the low CD4 group. Also
approaching significance were differences at positions 164 (N in high CD4, S in
low CD4) and 169 (I in high CD4, M in low CD4), near the structurally important
positions 165 and 167 in V2. Several other positions were identified in the C2, V4
and C5 regions, although none that was also identified in mouse-adapted clones.
Determining the significance of these mutations requires further sequence
analysis in a larger dataset in addition to functional analysis.
No significant difference in the average number of glycosylation sites was
detected between high and low CD4 groups, although there was a trend toward a
lower number of glycosylation sites in the low CD4 group (Figure 4a), which was
consistent with the loss of glycosylation sites observed in the mouse-adapted
virus populations. Sequence length (Figure 4.4b), which would be a
consequence of length variability in the variable loops, was also not significantly
different, but again showed a trend toward shorter sequence length in the low
CD4 group, which was perhaps linked to the number of glycosylation sites as
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glycosylation sites are often added and subtracted through insertion and deletion
in the variable loops.
I detected two distinct substitutions (I165R/K and D167N) in the V2 region
in mouse-adapted JRCSF that conferred the same structural change in Env
indicating that while V2 may be important in Env conformational changes and
phenotypes, multiple pathways exist to achieve the same result, analogous to V3
and co-receptor tropism. This may confound an attempt to identify specific sites
that are responsible for a specific phenotype. I therefore probed for differences in
amino acid composition in V2 by comparing differences in charge. I determined
the average charge within a subject of HIV-1 amino acid sequences for a region
encompassing positions 158-198 (HXB2 numbering), which includes both the
non-length-variable N-terminal region along with the length-variable region of V2.
Figure 4.4c illustrates the distribution of average V2 charges for each subject in
the high and low CD4+ T cell count groups. I found that V2 sequences from low
CD4+ T cell count subjects exhibited a significant increase in charge, which is
consistent with the types of mutations identified in V2 sequences of mouse-
adapted clones (I- to R/K or D to N), which also increase overall V2 charge in
JRCSF. Increased V2 charge was linked to X4 phenotypes in some but not all
sequences in subjects with X4 virus (data not shown).
4.4.7 Determining the prevalence of V3 antibody activity in sera from low
and high CD4+ T cell count subjects
I have identified a pathway to CXCR4 tropism in mouse-adapted variants
that may depend on reduced humoral immune pressure in late stage disease.
114
Given that I had Envs that exhibited exquisite neutralization sensitivity to V3
antibodies, and increased sensitivity to the CD4bs antibody b12, but not
antibodies targeting other epitopes, as with Env 6-39 compared to the parental
JRCSF (Table 4.1), I wanted to know if I could use these Envs to screen plasma
samples for the presence of V3 antibody and b12-like neutralization activity. In a
preliminary analysis of plasma from 8 subjects, 6 with low CD4+ T cell counts
and 2 with high CD4+ T cell counts, I found that 3 of 6 low CD4+ T cell count
sera, and 1 of  2 high CD4+ T cell count sera exhibited little to no neutralization
activity against either a sensitive or resistant Env, while the other sera exhibited
neutralization activity comparable to a V3 monoclonal antibody against the
sensitive clone only (Figure 4.5). These Envs represent useful tools to further
investigate larger sample sets for a link between the absence of specific
neutralizing antibody activity and contemporaneous HIV-1 Env phenotypes in
human subjects.
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4.5 DISCUSSION
In Chapter 3, I identified Env variants of the CCR5-tropic JRCSF isolate
that had evolved CXCR4 tropism in a humanized mouse model of HIV-1
infection. These X4 variants emerged in a “background” Env phenotype
characterized by increased sensitivity to V3-directed antibodies and increased
CD4 affinity, consistent with the lack of a strong humoral immune response in
these mice and the evolution of a more open conformation of Env that exposed
V3 (188, 192, 235). I hypothesized that the more open Env conformation that
conferred the background phenotype was a prerequisite for the acquisition of
CXCR4 tropism. Further analysis in Chapter 4 of both the background and X4
phenotypes revealed that conformational changes that increased V3 exposure
and CD4 binding affinity could allow low-level utilization of CXCR4 by Envs that
had yet to acquire tropism-defining V3 substitutions associated with efficient
CXCR4 use. I also found a correlation between increased positive charge in the
V2 region that controls V3 exposure, and low CD4+ T cell counts and the
presence of X4 virus in humans.
In Chapter 3, I established that the V3 loop of the X4 variants was
sufficient to confer X4 tropism in the mouse-adapted JRCSF. In this chapter, I
further defined the impact on CXCR4 tropism of specific combinations of the 4
substitutions in V3 associated with the tropism switch. Co-receptor tropism can
be predicted based on the composition of the V3 loop. In particular, basic amino
acid substitutions at positions 11 and/or 25, or an overall increase in positive
charge, is indicative of CXCR4 tropism (117, 129, 184). The single substitution of
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E25K, the only one of the 4 substitutions in X4 V3s that increased positive
charge, only appeared to diminish viral infectivity of the pseudotyped virus
(Figure 4.1). However, addition of the S11G substitution significantly increased
infectivity and measurable X4 tropism, although further work needs to be done to
confirm the effect of E25K alone. Positions 11 and 25 lie on opposite sides of the
V3 stem, with the charge-changing E25K substitution located near the V3 tip.
The increased positive charge of V3, and in particular at position 25 in V3, is
thought to determine specificity for CXCR4 by facilitating interaction with the
anionic surface of the extracellular loop 2 (ECL-2) of CXCR4 (23, 39, 306). The
X4-associated change F20I in V3 tip maintains a hydrophobic residue at that
position, which is thought to be important for ECL-2 interactions (50) and also
gp120/gp41 interactions in the un-liganded structure (317). Although this
substitution appeared to have a positive effect on both CCR4 and CXCR4
infectivity when added to the S11G and E25K substitutions, the functional
significance of this conservative change remains unclear and requires further
investigation. While S11G and E25K are sufficient to confer high-level CXCR4
infectivity, the additional substitutions F20I and S5N enhance overall infectivity
and in particular CXCR4 infectivity (Figure 4.1). The fitness advantage conferred
by this particular combination of four substitutions is consistent with our not
finding in the peripheral blood any other V3 variants with an X4 phenotype in our
analysis (Chapter 3). If I were able to examine the mesenteric lymph node, the
likely site of origin of these variants in the mouse, I may have identified the
immediate predecessor to the X4 phenotypes that emerged.
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The base of V3 is also thought to play a role in co-receptor engagement
(50). The S5N substitution in the base of V3, unlike the substitutions at positions
11, 20 and 25, was not unique to X4 variants and was found throughout the virus
population in mouse 6 (the mouse in which X4 variants emerged) at 92%
frequency. It was identified at a low frequency in only one other mouse, in which
X4 variants were not detected. This substitution represents a reversion to the
subtype B consensus. The S5N substitution is the first of a conserved triplet of
asparagines, and is in close proximity and just outside the binding pocket for one
of the sulfonated tyrosines in the N-terminus of the CCR5. Structural evidence
using a Y-sulfonated N-terminal peptide and antibody mimic indicates that the
latter 2 asparagines in this triplet directly interact with the C-terminal sulfonated
tyrosine, and while a dramatic acidic substitution at V3 position 5 had little effect
on binding of gp120 with these reagents (119), the consequences of a serine at
this position and it’s implication for coreceptor switching are unknown.
Interestingly, this substitution appeared to have a positive impact on relative X4
activity in combination with F20I and E25K, similar to S11G, and also exhibited
modest X4 activity alone, strongly suggesting it does play a role, although further
work is required to ascertain its impact on co-receptor switching.
The background phenotype in which X4 variants emerged exhibited
profound sensitivity to antibodies directed at V3 and showed increased CD4
binding conferred by structural rearrangements that resulted in a more open
conformation of Env (Table 4.1). b12 sensitivity is linked to increased CD4
binding affinity and macrophage tropism (72). I also found increased b12
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sensitivity in Envs that were highly sensitive to V3 antibodies along with having
increased CD4 binding affinity, further linking these structural changes with
phenotypes found in human infections, and in virus that may have escaped
antibody selective pressures by invading the CNS (72-74, 283).
Mutations in the non-length-variable N-terminal side of the V2 loop that
increased the overall positive charge of the loop (I165R/K or D167N) were
responsible for a major structural rearrangement that leads to increased V3
exposure, indicated by increased V3 antibody sensitivity. The V2 region of Env
has been shown in other studies to play a pivotal role in the conformational
masking of conserved epitopes targeted by neutralizing antibody responses and
those directed at V3 in particular (44, 225, 270, 315). It has been demonstrated
in multiple settings that removal of antibody selective pressures results in the
selection of mutations in V2 that result in a more open, neutralization sensitive
Env conformation that has enhanced CD4 and co-receptor engagement through
exposure of these binding sites (9, 83, 127, 164, 188, 235, 315). The recently-
identified gp120 trimer-specific, potent, broadly neutralizing antibody PG9 (and
the somatic variant PG16) recognizes an epitope involving the conserved V1/V2
base and conserved regions of the V2 and V3 loops, or at least is dramatically
affected by changes in these regions. PG9 also exhibits increased affinity to
trimers with an E168K substitution, perhaps a result of a conformational change
(299). This provides additional evidence that basic substitutions at specific sites
in V2 can increase neutralization sensitivity to antibodies with specificities for this
region and V3. Substitutions in the V1/V2 region have also been shown to play a
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compensatory role by increasing infectivity in viruses that acquire V3 mutations
on the pathway to CXCR4 tropism that confer a loss of infectivity (199, 215). The
question of whether or not this involves increased dependence on the N-terminus
of the co-receptor requires further investigation. The changes I identified in V2,
while not conferring a detectible increase in CD4 binding affinity in a competitive
inhibition assay with an anti-CD4 antibody (Table 4.1), were sufficient to increase
relative infectivity when CD4 was limiting, analogous to a pathway that may
confer some level of macrophage tropism. Thus the same conformational change
in gp120 may have three related effects: first, changes may allow more efficient
CD4 binding for more rapid growth in T cells (presumably the source of the
selection); second, more efficient CD4 binding may also allow entry into cells with
fewer CD4 molecules; and third, the altered conformation may allow increased
interaction with CXCR4, which may also depend on increased CD4 binding
affinity. Because the initial gp120:CD4 interaction is weak and likely requires the
binding of multiple CD4 molecules in order to increase avidity for most primary
isolates, conformational changes that allow increased CD4 affinity can
compensate for the reduced avidity when CD4 molecules are scarce, such as on
macrophages (327). An alternative hypothesis is that changes in V2 which
increase positive charge may enhance interactions, in a less specific manner,
with negatively charged cell membrane-associated molecules, such as heparan
sulfate proteoglycans, thereby increasing avidity when CD4 is low, although the
data are conflicting on the positive effect of heparan sulfate in HIV-1 binding to
target cells (194, 216, 296, 297).
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When I compared V2 sequences from subjects with low CD4+ T cell
counts, and therefore with a high risk of having X4 virus, to those with high CD4+
T cell counts, I found an increase in overall V2 charge in the low CD4+ T cell
count subjects. Because more than one mutation in the mouse-adapted virus, in
an isogenic viral background, was sufficient to confer the same phenotype, it is
likely that a basic or positive charge at any of multiple sites in V2 can confer this
phenotype. This is consistent with a lack of detection of a signal at a single
position in V2 that distinguishes these high and low CD4 environments. Whether
or not variants with increased V2 charge show the same phenotypes, either
increased V3 antibody neutralization or increased infectivity when CD4 is limiting,
is an important question.
Increased CD4 binding affinity and sensitivity to neutralization by soluble
CD4 and antibodies, phenotypes also associated with macrophage-tropism, have
been linked to co-receptor switching in simian/human immunodeficiency virus
(SHIV) Rhesus macaque models (114). In addition, X4 variants have been
shown to be more neutralization sensitive compared to R5 variants in human
infections (29, 169). Emergence of X4 SHIV variants in the Rhesus macaque
was shown to follow, rather than precede, the development of an
immunosuppressed environment and coincided with an increase in a
macrophage-tropic phenotype (114, 115). Thus, the same environmental change,
immunosuppression, may link macrophage tropism, as defined by increased CD4
binding affinity and the ability to use low levels of CD4, and X4 emergence if both
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of these phenotypes depend on the same conformational changes which are
selected against by humoral immune pressure.
Evolution of X4 tropism may depend on the same functional changes that
confer macrophage tropism. This is demonstrated in Figure 4.3a and b, which
show that increasing V3 antibody sensitivity and CD4 binding affinity correlate
with increased infectivity on cells expressing only CD4 and CXCR4. This
pathway suggests a mechanism of X4 evolution whereby substitutions, such as
those at positions 165 or 167, that result in conformational unmasking of receptor
and co-receptor binding sites, and which may increase CD4 binding affinity and
infectivity, compensate for weak or non-specific interactions with the alternative
co-receptor CXCR4. A reduced dependance on the specific interactions between
V3 and coreceptor is indicated by increased relative resistance to the CXCR4
inhibitor AMD3100, of the Envs with R5 V3s that exhibit some infectivity using
CXCR4, compared to bona fide X4 viruses (Figure 4.3c). AMD3100 specifically
inhibits the interactions between V3 and the extracellular loop, but not
necessarily interactions with the N-terminus of the co-receptor, which may be
how these R5 viruses are interacting with CXCR4 (69). As CD4 binding and V3
exposure become more pronounced, the ability to utilize CXCR4 is increased.
The pathway of X4 and macrophage tropism bifurcates when V3 mutations
accumulate to a degree that CXCR4 engagement is enhanced at the expense of
CCR5 engagement. Thus the early stages of X4 evolution may be shared with
those of macrophage tropism evolution. This is consistent with some evidence
linking the emergence of macrophage-tropic virus in tissue other than the brain
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with late stage disease (97, 114, 124), although further investigation is required
to link the emergence macrophage tropism to immunosuppression.
Why do X4 variants emerge? The early stages of X4 evolution allowing
low-level utilization of CXCR4 may allow expansion of host cell range to cells that
only express CXCR4 and not CCR5, such as naïve T cells. While the initial
viruses infecting these cells may exhibit reduced replication capacity, at first, in
these cell types, un-rivaled competition for this cellular pool may allow a less fit
viral population time to evolve V3 changes that increase replication capacity in
this cell type and fitness relative to R5 variants. This model is consistent with the
observation made in Chapter 2 that X4 variants in the population represent a
clonal expansion. This is presumably because of the jump in viral fitness when
variants acquire the correct combination of V3 mutations, an event that needs to
occur only once. However, the evolution of this initially poorly fit virus in naïve T
cells likely requires an immunodeficient host that is either incapable of
neutralizing the newly-evolved, neutralization-sensitive and promiscuous virus or
incapable of monitoring infection of this new target cell population.
Linking genetic pathways of these phenotypes to the environmental
change of reduced antibody pressure will require parallel tracking of the host
antibody response and the genetic and phenotypic changes in the viral
population. Alternatively, a cross-sectional approach with a large enough dataset
could also lend further evidence to this connection. The exquisitely V3-antibody-
sensitive Envs identified in this study, along with the parental JRCSF Env, can be
used to probe for specific antibody neutralization activity in patient sera. The
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neutralization profile of the sera can then be correlated to the genetic and
phenotypic features of the contemporaneous virus. Ultimately, however, proof of
this link will require evolutionary modeling in the appropriate system where
specific immune pressures can be carefully controlled.
It is also possible that while this hypothesis for the evolutionary path of
CXCR4 tropism might be validated for Envs evolving in the absence of a specific
humoral response, different selective pressures and a different evolutionary
pathway may be operating in humans. It is also possible that the correlates
identified in the perpheral blood, such as a lack of a specific antibody
neutralization activity may not be relevant. Instead, what may be more relevant is
the local environment, either in a specific tissue or cellular compartment, which
may select for or potentiate X4 evolution. Further work is needed to understand
the local environmental factors at play that select for phenotypic variants in the
compartment where they originate, which is still unknown for X4 variants.
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Table 4.1: Neutralization phenotypes of selected mouse-adated and mutant Env
a Data from Chapter 3. For mouse adapted clones 6-39, 6-38 and 6-60, the co-
receptor phenotype predicted by the V3 sequence is indicated in parenthesis
bData from Chapter 3. Sensitvity was tested using 1 or more of 3 antibodies
directed at overlapping epitopes at the tip of V3 (447-52D, 19b, 2.1E) all results
were concordant
cLeu3a competatively inhibits Env binding
Table 1: Neutralization phenotypes of selected mouse-adapted and mutant Envs
Env clone
V3 antibody 
sensitivityb
CD4 binding 
affinity (mAb 
Leu3a 
resistance)c
mAb b12 
sensitivity
mAb 4E10 
sensitvity
mAb 2G12 
senstivity
JRCSF wt - - - + +
6-39 (R5)a +++ + ++ + -
6-38 (R5)a +++ + ++ ND ND
6-60 (X4)a +++ ND ND ND ND
JRCSF I165R + +/- - + +
JRCSF D167N + +/- - + +
JRCSF N386K - - + + +
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Figure 4.1. X4 and R5 activity JRCSF V3 mutants. Entry activity of virus
pseudotyped with various Env mutants on U87.CD4.CCR5 and U87.CD4.CXCR4
was quantitated by luciferase expression. Background was set to un-infected
cells. x-Axis labels indicate the Env clone or V3 amino acid substitution and
position (1-35) and in JRCSF Env. JRCSF is the wild type R5 Env, 6-45 and 6-60
are JRCSF-derived, mouse-adapted X4 viruses. NL4-3 is a prototypical X4 virus.
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Figure 4.2. Entry activity of pseudotyped virus on cells expressing different levels
of CD4 and CCR5. Affinofile cells, 293T cells with differentially inducible CD4 and
CCR5 expression, were infected with pseudovirus containing a luciferase
expression cassette. Viral entry activity was quantitated by luciferase expression
(relative light units (RLU)). A-D. Entry activity at different CD4 (x-axis) and CCR5
(y-axis) expression levels, indicated as the log(10) antibody binding sites/cell. E.
Entry activity of pseudovirus at the lowest CD4 and CCR5 expression levels
relative to entry at the low CCR5 and the highest CD4 expression level (104.7
ABS/cell and not presented in A-D).
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Figure 4.3. Relative X4 and R5 activity and AMD3100 resistance of JRCSF-
derived mouse-adapted and mutant Envs. Luciferase activity was assessed for
pseudovirus infecting either U87.CD4.CCR5 (x-axis) and U87.CD4.CXCR4 (y-
axis) cells and plotted as the log(10) RLU. A) Infectivty using CD4 and CXCR4
relative to infectivity usingCD4 and CCR5 using data plotted in (B). B) Infectivity
on using CD4 and CXCR4 or CCR5. V3 antibody sensitivity and CD4 binding
affinity are as indicated in Table 1. V3 genotype (V3 geno.) was determined
using X4R5 PSSM (Jensen). C) % inhibiton by a 2.5uM dose of AMD3100.
128
Figure 4.4. Sequence characteristics of V2-V5 region of Env from HIV-1 infected
subjects with high and low CD4+ T cell counts. Subjects were divided in to two
groups based on CD4+ T cell count (x-axis). High: >240; low: <240. A. Average
number of N-linked glycosylation sites in the V2-V5 region. Potential N-linked
glycosylation sites (PNGL) were predicted using N-Glycosite accessed through
the Los Alamos National Laboratories HIV-1 Database website which infers a
PNLGS in NXT/S motifs where X≠ P. B. Average amino acid length for the V2-V5
region. C. Average charge of the V2 loop (HXB2 positions 158-198). V2 charge
was significantly different between the sequences obtained from subjects with
high and low CD4+ T cell counts.
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Figure 4.5. Neutralization activity in HIV-1-infected patient sera. Neutralization
curves for sera against mouse-derived clone 6-39 (green line), which is highly
sensitive to V3 antibodies, and JRCSF (blue line) pseudotyped virus. The viral
backbone used contains antiviral resistance mutations. Entry was measured as
luciferase activity in TZM-BL cells which contain a viral Tat-responsive luciferase
expression cassette. Infectivity was measure relative to entry activity in the absence
of serum.
Chapter 5
Conclusions and Future Directions
In this work, I have attempted to shed more light on how HIV-1 Env
evolution is shaped by its interaction with a dynamic host environment,
particularly the evolving immune response, which is itself shaped by pathogenic
effects of the virus. In Chapter 2, I showed that the diverse population of Env
variants that develops in the peripheral blood over the course of chronic infection
does not represent compartmentalized populations, based on the observation
that individual variants decayed at the same rate upon initiation of therapy. I also
showed how the gain-of-function phenotype of CXCR4 tropism, which is
correlated with immunosuppression, affects the viral population. I found that X4
variants emerge from a single founder and that these variants can co-exist with
R5 variants in the host yet replicate in an overlapping cellular compartment.
These results indicated that diverse Env phenotypes were not driving
compartmentalization in different cell types, as might be expected if CXCR4 and
CCR5 are differentially expressed on different susceptible cellular subsets.  In
Chapter 3, I characterized the evolution of Env in a humanized mouse model,
which may be representative of late stage immunosuppression in humans. There
131
was no detectible HIV-1-specific antibody response in these animals, and it is
possible that this is similar to the environment encountered by HIV-1 in humans
when CD4+ T helper cell counts are very low and when B cell function has been
shown to be impaired. In this environment in the mouse, Env evolved in a
manner indicative of a reduced or absent humoral immune response. These
changes included a widely observed opening up of Env conformation and a
switch in co-receptor tropism in one population. Given these observations, in
Chapter 4 I began to explore the factors responsible for the emergence of virus
with CXCR4 tropism by dissecting the relationship between different Env
phenotypes associated with immunosuppression and CXCR4 tropism. I found
that an open Env conformation and increased CD4 binding potentiated entry
using CXCR4 and may be a prerequisite phenotype for evolution of CXCR4
tropism in general. I also compared some features of virus adapted to the
immunodeficient environment in the mouse to HIV-1 from immunosuppressed
individuals, a high percentage of whom had CXCR4-tropic virus, and found that
basic changes (that increase charge) in V2 are common among Env variants
evolving in immunosuppressed environments in both humans and the humanized
mouse.
While the hypothesis that a the loss of a specific antibody response is
required for, or at least potentiates, CXCR4-tropism evolution remains viable,
additional evidence is required to prove the causative link between the loss of
specific antibody pressures and the structural and phenotypic changes that allow
HIV-1 to expand its host cell range and ultimately optimize its CXCR4 tropism.
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The environmental pressures that select for CXCR4 tropism remain unknown,
and are not directly addressed by this hypothesis. It may be determined that
evolution of CXCR4 tropism is independent of antibody selective pressures and
only dependent on target cell availability or other selective forces. Also, the
relationship between CXCR4 emergence and disease progression remain
unclear and could provide clues to the selection of CXCR4-tropism emergence.
5.1 Origin of V3 antibodies.
The more open Env conformation that evolves in the absence of antibody
selective pressure is thought to resemble more closely the CD4-bound state of
gp120 that is primed to bind the coreceptor. One consequence of a more open
Env conformation, along with enhanced CD4 binding, sensitivity to soluble CD4,
and exposure of other CD4 binding-induced epitopes, is the exposure of V3 and
increased V3 antibody sensitivity (9, 77, 192, 235, 270, 313). V3 has also been
found to be a potent antigen as evidenced by the abundance of V3 antibodies in
patient sera (51, 261, 293). The relative insensitivity of primary isolates to anti-V3
antibodies (13, 192, 293) indicates that the antigen responsible for eliciting this
antibody may not be in the neutralization-resistant virion-associated trimer, but
rather may be gp120 monomers shed from the cell or particle. V3 antibodies in
particular show greatly increased binding to monomers compared to membrane-
associated trimers (82). Furthermore, antibody titers generated from monomer-
based vaccines show poor neutralization activity. Thus it is likely that the
presence of V3 antibody, perhaps by accident of gp120 shedding, keeps Env
from evolving a more open conformation.
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I should note here that these findings point toward a mechanism of
epitope masking that involves inter-molecular interactions between members of
the trimer. Whether or not this is the case may be addressed by assessing the
phenotypes of heterotrimers assembled with different Env mutants (259). Do
Envs that exhibit the loss of conformational masking due to different mechanisms
complement each other in a trimer?
5.2 Characterizing the humoral immune response in late stage infection.
The humoral immune response is impaired in HIV-1 infection, particularly
in late stage disease (56, 57, 153, 246, 281). However, the extent to which the
ability to produce specific antibodies (such as those directed at V3) is lost when
the CD4+ T cell count is very low remains unclear. As discussed in Chapter 4, I
have generated reagents that may be used to probe for the neutralization activity
of specific antibodies in patient sera. Screening with a highly V3 antibody-
sensitive Env clone can be used to identify the loss of this activity. This assay
can be refined by further confirming the breadth of sensitivity of this Env, perhaps
by depletion of V3-specific antibodies from sera. We can then ask the question of
whether or not V3 antibody-deficient sera correlate with the presence of specific
Env phenotypes, such as the loss of sensitivity to specific antibodies and other
phenotypes that are on the path to CXCR4 tropism, as described in Chapter 4.
This type of experimental approach can also be used in the case where
longitudinal samples are available that span the time when an X4 virus emerges.
Are specific antibodies lost prior to CXCR4 emergence? Do V2 mutations that
open Env conformation precede and show linkage to the emergent CXCR4 env
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variant? Finally, a comprehensive assessment of the differences in neutralization
sensitivities of HIV-1 populations in which CXCR4 variants have emerged,
compared to populations that do not harbor CXCR4 variants, should be carried
out, as the current data on this issue are incomplete and conflicting (29, 31, 38,
114, 158, 169, 190).
5.3 Modeling of coreceptor switching.
The role that background phenotypes play in the evolution of CXCR4
tropism can be modeled directly in vitro. Do either of the V2 mutations identified
in the humanized mouse (described in Chapter 3), or any V2 mutations identified
in human infections with low CD4+ T cell counts (described in Chapter 4), lead to
more rapid evolution of CXCR4 tropism in vitro when this phenotype is selected
for? The role that particular antibody specificities play in inhibiting Env phenotypic
evolution that leads to CXCR4 tropism can also be addressed more directly by
modeling evolution in vitro using different monoclonal antibodies as selective
agents (8, 173, 270). These types of experiments can be extended to in vivo
models, using passive immunization in models that lack a natural antibody
response, and depletion of specific B cells or antibodies in models that do.
The interactions between the co-receptor and Envs with background or
intermediate CXCR4 tropism phenotypes requires further investigation. It is still
unclear how CXCR4 mediates fusion of a virus with a CCR5-tropic V3 loop. One
hypothesis is that Interactions with the new coreceptor are mediated
predominantly by the N-terminus of the coreceptor. This is suggested by the
observation that the CXCR4-binding inhibitor AMD3100 only partially impairs the
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low level CXCR4-mediated infectivity of Envs with R5 V3 sequences. This can be
tested directly using a peptide that mimics the sulfonated N-terminus of the
coreceptor, binds to gp120, and inhibits its interactions with this portion of the
coreceptor.
5.4 Compartmentalization and the tissue of origin.
A major factor that likely plays a role in CXCR4 tropism emergence, and also in
pathogenesis, is compartmentalization. Where in the body is CXCR4 tropism first
selected and in what cell types? Other than a few studies examining autopsy
tissue, and only one study that adequately addresses compartmentalization of X4
virus in different cell type (15, 257), there is very little evidence in people that
points to the compartment where X4 viruses first emerge. Understanding this
aspect of evolution will not only shed light on the selective pressures driving X4
emergence, but also on the pathogenic role of X4 virus. In Chapter 2, I observed
that X4 and R5 virus populations were not highly compartmentalized in cross-
sectional analysis, making clear that pinpointing the source will be challenging.
While studies in SHIV models in which a tropism switch has occurred have
provided the opportunity to explore this question (237), it has not been rigorously
explored in this setting. Only one study that I am aware of has adequately
addressed the question of the tissue compartment origin of CXCR4 tropism in
humans (257). In Salemi, at al, longitudinal analysis of sequences from the
peripheral blood was coupled with sequences obtained from post mortem tissue
from therapy naïve children that had died of AIDS. Using phylogenetic
reconstruction, they found that the X4 variants first emerged in the thymus. This
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is not surprising given that this organ harbors highly HIV-susceptible CXCR4-
expressing thymocytes and a very limited number of CCR5-expressing cells (25,
138, 321). They also found X4 evolution to be a sequential process, with
mutations in the V1/V2 and C2 regions appearing first, similar to my findings in
the humanized mouse model. The findings in this study are consistent with the
hypothesis that X4 variants take hold in the CXCR4+ CCR5- population of CD4+
T cells,  a cell type that is abundant in the thymus, an organ in which active viral
replication has observed pathogenic consequences.  Whether or not the
observation of a thymic origin of X4 virus extends to adults, in whom the cellular
population of this organ is altered, remains unclear.  While X4 variants may be
highly pathogenic in the thymus, this does not necessarily indicate it is the tissue
of origin in immunosuppressed adults. Identifying the environmental factors, both
systemic and in the tissue and cellular compartments, that select for the changes
in the Env phenotypes that coincide with disease progression will aid not only in
our understanding HIV-1 pathogenesis but also in our understanding of the
fundamental features of enveloped virus evolution.
5.5 Exceptions that prove the rule.
The environmental and Env-intrinsic constraints on Env evolution can also
be better understood by examining the factors that limit the emergence of
specific phenotypes, such as CXCR4 tropism. For example, the frequent
emergence of CXCR4-tropic virus in late stage disease is a typical feature of
subtypes B and D, but not subtype C HIV-1 (121, 224). This may be due to
intrinsic structural constraints of subtype C (217). Further exploration of the
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differences in the structural constraints between subtypes B, C and D may
provide clues to the genetic barriers to X4 emergence in these different subtypes.
Differences in the environments experienced by different subtypes may also be a
factor in determining the different frequencies of Env phenotypes. What is the
impact of the fact that the population supporting subtype B infections is relatively
homogeneous compared to that supporting subtype C infections?
Finally, what factors limit the transmission of specific phenotypic variants,
such as CXCR4- and macrophage-tropic viruses? Understanding the
environmental factors that select for the highly CD4-dependent R5 virus that is
typically responsible for establishing infection will not only inform the
development of transmission prevention strategies, but will also tell us something
about the environmental requirements of the phenotypic variants that are not
typically transmitted. Conversely, exceptions often prove the rule. CXCR4-tropic
variants are transmitted in a limited number of cases and often lead to rapid
disease progression. What are the characteristics of the recipients of the
phenotypic variants that might lend clues to the selective pressures driving its
emergence?
A significant amount of data has been collected in an attempt to answer
many of the questions posed above, although a definitive answer to why HIV-1
Env evolves on its relatively predictable path remains elusive. One task that
remains is a more thorough re-examination of the assumptions, especially those
that have become dogma, some of which are based on weak or possibly
misinterpreted data. Testing the hypotheses that I have presented and that flow
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from my results will go a long way toward a deeper understanding of Env protein
evolution during late-stage HIV-1 infection.
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